[ { "key": "Z3Z3742H", "version": 12189, "library": { "type": "group", "id": 251615, "name": "CentreImage", "links": { "alternate": { "href": "https://www.zotero.org/groups/centreimage", "type": "text/html" } } }, "links": { "self": { "href": "https://api.zotero.org/groups/251615/items/Z3Z3742H", "type": "application/json" }, "alternate": { "href": "https://www.zotero.org/groups/centreimage/items/Z3Z3742H", "type": "text/html" } }, "meta": { "createdByUser": { "id": 14022664, "username": "TeodoraCHUSJ", "name": "", "links": { "alternate": { "href": "https://www.zotero.org/teodorachusj", "type": "text/html" } } }, "creatorSummary": "Zauche et al.", "parsedDate": "2026-12", "numChildren": 1 }, "data": { "key": "Z3Z3742H", "version": 12189, "itemType": "journalArticle", "title": "Neonatal intensive care unit admission among infants born full-term to CDC's COVID-19 Vaccine Pregnancy Registry participants: A matched cohort study", "creators": [ { "creatorType": "author", "firstName": "Lauren Head", "lastName": "Zauche" }, { "creatorType": "author", "firstName": "Sabrina A.", "lastName": "Madni" }, { "creatorType": "author", "firstName": "David K.", "lastName": "Shay" }, { "creatorType": "author", "firstName": "Christine K.", "lastName": "Olson" }, { "creatorType": "author", "firstName": "Aliza", "lastName": "Machefsky" }, { "creatorType": "author", "firstName": "Shana E.", "lastName": "Godfred Cato" }, { "creatorType": "author", "firstName": "Andrea J.", "lastName": "Sharma" } ], "abstractNote": "To estimate incidence of neonatal intensive care unit (NICU) admission among infants born to women receiving COVID-19 vaccines during pregnancy versus among infants born to unvaccinated women. We matched full-term infants from the United States Centers for Disease Control and Prevention's (CDC) COVID-19 Vaccine Pregnancy Registry (C19VPR) to full-term infants from CDC's Pregnancy Risk Assessment Monitoring System (PRAMS) with participant report of NICU admission available. We used 1:1 convenience sampling to match by maternal age, race, and ethnicity (n = 5,487 pairs). Adjusted incidence ratios (aIR) for NICU admission were calculated using Poisson regression; sensitivity analyses included a state-based match. NICU admission incidence was lower among C19VPR infants than PRAMS infants (7.7% vs 11.3%, aIR: 0.81, 95% CI: 0.65, 0.99). The highest aIR estimate generated through sensitivity analyses was 0.86 (95% CI: 0.67, 1.11). No evidence for an increased risk of NICU admission was found among infants born to vaccinated versus unvaccinated women.", "publicationTitle": "Human Vaccines & Immunotherapeutics", "publisher": "", "place": "", "date": "2026-12", "volume": "22", "issue": "1", "section": "", "partNumber": "", "partTitle": "", "pages": "2636365", "series": "", "seriesTitle": "", "seriesText": "", "journalAbbreviation": "Hum Vaccin Immunother", "DOI": "10.1080/21645515.2026.2636365", "citationKey": "", "url": "", "accessDate": "", "PMID": "41774852", "PMCID": "PMC12959207", "ISSN": "2164-554X", "archive": "", "archiveLocation": "", "shortTitle": "Neonatal intensive care unit admission among infants born full-term to CDC's COVID-19 Vaccine Pregnancy Registry participants", "language": "eng", "libraryCatalog": "PubMed", "callNumber": "", "rights": "", "extra": "", "tags": [ { "tag": "*SARS-CoV-2 vaccine/dt [Drug Therapy]" }, { "tag": "*hospital admission" }, { "tag": "*neonatal intensive care unit" }, { "tag": "*pregnancy" }, { "tag": "Adult", "type": 1 }, { "tag": "COVID-19", "type": 1 }, { "tag": "COVID-19 Vaccines", "type": 1 }, { "tag": "COVID-19 vaccine", "type": 1 }, { "tag": "Centers for Disease Control and Prevention, U.S.", "type": 1 }, { "tag": "Cohort Studies", "type": 1 }, { "tag": "Female", "type": 1 }, { "tag": "Humans", "type": 1 }, { "tag": "Incidence", "type": 1 }, { "tag": "Infant, Newborn", "type": 1 }, { "tag": "Intensive Care Units, Neonatal", "type": 1 }, { "tag": "Male", "type": 1 }, { "tag": "Neonatal intensive care unit", "type": 1 }, { "tag": "Pregnancy", "type": 1 }, { "tag": "Pregnancy Complications, Infectious", "type": 1 }, { "tag": "Registries", "type": 1 }, { "tag": "SARS-CoV-2", "type": 1 }, { "tag": "SAS version 9.4" }, { "tag": "United States", "type": 1 }, { "tag": "Vaccination", "type": 1 }, { "tag": "Young Adult", "type": 1 }, { "tag": "adult" }, { "tag": "article" }, { "tag": "birth weight" }, { "tag": "cohort analysis" }, { "tag": "controlled study" }, { "tag": "coronavirus disease 2019/dt [Drug Therapy]" }, { "tag": "data analysis software" }, { "tag": "elasomeran/dt [Drug Therapy]" }, { "tag": "ethnicity" }, { "tag": "female" }, { "tag": "gestational age" }, { "tag": "gestational diabetes" }, { "tag": "human" }, { "tag": "ibacovavec/dt [Drug Therapy]" }, { "tag": "incidence" }, { "tag": "infant" }, { "tag": "male" }, { "tag": "maternal age" }, { "tag": "maternal hypertension" }, { "tag": "maternal vaccination", "type": 1 }, { "tag": "nullipara" }, { "tag": "obesity" }, { "tag": "pregnancy", "type": 1 }, { "tag": "risk assessment" }, { "tag": "sensitivity analysis" }, { "tag": "tozinameran/dt [Drug Therapy]" }, { "tag": "vaccine safety", "type": 1 } ], "collections": [], "relations": { "dc:replaces": "http://zotero.org/groups/251615/items/BJJM6KSG" }, "dateAdded": "2026-04-07T19:56:54Z", "dateModified": "2026-04-07T20:20:12Z" } }, { "key": "JXCQIYNG", "version": 12244, "library": { "type": "group", "id": 251615, "name": "CentreImage", "links": { "alternate": { "href": "https://www.zotero.org/groups/centreimage", "type": "text/html" } } }, "links": { "self": { "href": "https://api.zotero.org/groups/251615/items/JXCQIYNG", "type": "application/json" }, "alternate": { "href": "https://www.zotero.org/groups/centreimage/items/JXCQIYNG", "type": "text/html" } }, "meta": { "createdByUser": { "id": 14022664, "username": "TeodoraCHUSJ", "name": "", "links": { "alternate": { "href": "https://www.zotero.org/teodorachusj", "type": "text/html" } } }, "creatorSummary": "Wraae et al.", "parsedDate": "2026-03-22", "numChildren": 1 }, "data": { "key": "JXCQIYNG", "version": 12244, "itemType": "journalArticle", "title": "Use of antiemetics in early pregnancy 2012-2022: A cross-sectional study", "creators": [ { "creatorType": "author", "firstName": "Katrine Bak", "lastName": "Wraae" }, { "creatorType": "author", "firstName": "Nanna Roed", "lastName": "Ballegaard" }, { "creatorType": "author", "firstName": "Mie Lærkeholm", "lastName": "Hede" }, { "creatorType": "author", "firstName": "Line", "lastName": "Buchgreitz" }, { "creatorType": "author", "firstName": "Ane Lilleøre", "lastName": "Rom" }, { "creatorType": "author", "firstName": "Hanne Kristine", "lastName": "Hegaard" }, { "creatorType": "author", "firstName": "Nina Olsén", "lastName": "Nathan" } ], "abstractNote": "AIM: Nausea and vomiting in pregnancy impact quality of life, yet many pregnant women feel dismissed by healthcare professionals, despite the safety of first-line antiemetic treatments for both mother and fetus. Therefore, this study aims to describe the prevalence of patient-reported antiemetic use in early pregnancy in Copenhagen, Denmark, the changes in use over two time periods, and the maternal characteristics of users and non-users.\nMETHODS: We analysed patient-reported data on antiemetic use during early pregnancy and maternal characteristics from the Copenhagen Pregnancy Cohort (2012-2022). Descriptive statistics were applied to assess the prevalence, changes in use over two time periods and differences between users and non-users.\nRESULTS: Among 40 856 pregnancies, 1.0% (n = 412) reported using antiemetics in early pregnancy. Metoclopramide was the most used, reported by 0.2% (n = 93). The number of pregnancies with patient-reported antiemetic use doubled from 0.7% in 2012-2017 to 1.4% in 2018-2022. Among users, 83.3% received monotherapy, and 74.1% used antiemetics daily. Compared with non-users, a significantly higher proportion of antiemetic users scored <50 on the World Health Organization Five Well-Being Index (66.6% vs. 20.5%, p < .001) and to a higher extent reported sick leave (68.0% vs. 14.1%, p < .001).\nCONCLUSION: We found a low but rising prevalence of antiemetic use in early pregnancy, and the treatment often deviated from clinical guidelines. Antiemetic users differed from non-users on several maternal characteristics, with a higher proportion reporting somatic and psychiatric disorders, as well as poorer mental well-being, despite antiemetic treatment.", "publicationTitle": "British Journal of Clinical Pharmacology", "publisher": "", "place": "", "date": "2026-03-22", "volume": "", "issue": "", "section": "", "partNumber": "", "partTitle": "", "pages": "", "series": "", "seriesTitle": "", "seriesText": "", "journalAbbreviation": "Br J Clin Pharmacol", "DOI": "10.1002/bcp.70516", "citationKey": "", "url": "", "accessDate": "", "PMID": "41866339", "PMCID": "", "ISSN": "1365-2125", "archive": "", "archiveLocation": "", "shortTitle": "Use of antiemetics in early pregnancy 2012-2022", "language": "eng", "libraryCatalog": "PubMed", "callNumber": "", "rights": "", "extra": "", "tags": [ { "tag": "*antiemetic agent" }, { "tag": "*first trimester pregnancy" }, { "tag": "*pregnancy" }, { "tag": "*prevalence" }, { "tag": "Denmark" }, { "tag": "adult" }, { "tag": "antiemetics", "type": 1 }, { "tag": "article" }, { "tag": "clinical practice guideline" }, { "tag": "cohort analysis" }, { "tag": "cross-sectional study" }, { "tag": "female" }, { "tag": "health care personnel" }, { "tag": "human" }, { "tag": "major clinical study" }, { "tag": "maternal characteristics", "type": 1 }, { "tag": "medical leave" }, { "tag": "mental disease" }, { "tag": "metoclopramide" }, { "tag": "monotherapy" }, { "tag": "morning sickness" }, { "tag": "nausea and vomiting" }, { "tag": "pregnancy", "type": 1 }, { "tag": "pregnant woman" }, { "tag": "prevalence", "type": 1 }, { "tag": "psychological well-being" }, { "tag": "quality of life" }, { "tag": "therapy" } ], "collections": [ "34HIUU9M" ], "relations": { "dc:replaces": "http://zotero.org/groups/251615/items/E45X34EH" }, "dateAdded": "2026-04-07T19:56:54Z", "dateModified": "2026-04-07T20:20:11Z" } }, { "key": "VUA7KX4Z", "version": 12175, "library": { "type": "group", "id": 251615, "name": "CentreImage", "links": { "alternate": { "href": "https://www.zotero.org/groups/centreimage", "type": "text/html" } } }, "links": { "self": { "href": "https://api.zotero.org/groups/251615/items/VUA7KX4Z", "type": "application/json" }, "alternate": { "href": "https://www.zotero.org/groups/centreimage/items/VUA7KX4Z", "type": "text/html" } }, "meta": { "createdByUser": { "id": 14022664, "username": "TeodoraCHUSJ", "name": "", "links": { "alternate": { "href": "https://www.zotero.org/teodorachusj", "type": "text/html" } } }, "creatorSummary": "Wang et al.", "parsedDate": "2026", "numChildren": 1 }, "data": { "key": "VUA7KX4Z", "version": 12175, "itemType": "journalArticle", "title": "Associations between antenatal corticosteroids and neonatal morbidities in a prospective cohort: role of course, timing, and gestational age", "creators": [ { "creatorType": "author", "firstName": "Xuanshu", "lastName": "Wang" }, { "creatorType": "author", "firstName": "Kailun", "lastName": "Zhang" }, { "creatorType": "author", "firstName": "Xiaomin", "lastName": "Ye" }, { "creatorType": "author", "firstName": "Xiwen", "lastName": "Wang" }, { "creatorType": "author", "firstName": "Ling", "lastName": "Wang" }, { "creatorType": "author", "firstName": "Liya", "lastName": "Ma" }, { "creatorType": "author", "firstName": "Hui", "lastName": "Liang" }, { "creatorType": "author", "firstName": "Quanfu", "lastName": "Zhang" }, { "creatorType": "author", "firstName": "Xu", "lastName": "Chen" }, { "creatorType": "author", "firstName": "Ruoqing", "lastName": "Chen" } ], "abstractNote": "BACKGROUND: Antenatal corticosteroids (ACS) have been widely used to enhance fetal lung maturation in pregnant women at risk of preterm delivery, but gaps remain in understanding how number of courses, gestational age at the first dose, and last dose-to-delivery interval affect neonatal morbidities across different gestational age groups. This study aimed to investigate the associations between ACS, particularly the number of courses, gestational age at the first dose, and last dose-to-delivery interval, and neonatal morbidities.\nMETHODS: This prospective study included 78,642 singleton infants born at 29-43 weeks of gestation between July 2018 and June 2024. Detailed information of ACS exposure and neonatal morbidities was obtained from electronic health records. Logistic regression was applied to estimate the odds ratios (ORs) and 95% confidence intervals (CIs) for neonatal morbidities. Subgroup analyses were performed by stratifying the gestational age at birth.\nRESULTS: A total of 2827 (3.59%) infants were exposed to ACS. Compared with unexposed infants, those exposed to ACS had higher risks of respiratory, metabolic, infectious/inflammatory, and neurological morbidities, but not of asphyxia. Multiple ACS courses demonstrated the strongest association with higher risk of neurological morbidity (OR, 2.99; 95% CI 1.68-5.31), along with increased risks of metabolic (OR, 1.43; 95% CI 1.12-1.83) and infectious/inflammatory morbidities (OR, 1.45; 95% CI 1.11-1.89). The timing of the first ACS dose was associated with increased risks of specific neonatal morbidities, regardless of the gestational age at initiation. A last dose-to-delivery interval of 14 days or more was associated with higher risks of metabolic (OR, 1.25; 95% CI 1.14-1.37), infectious/inflammatory (OR, 1.26; 95% CI 1.13-1.40), and neurological (OR, 1.84; 95% CI 1.31-2.59) morbidities. No association was found for infants born before 34 weeks.\nCONCLUSIONS: ACS exposure, particularly multiple courses or a last dose-to-delivery interval of 14 days or more, was associated with higher risks of neonatal morbidities among infants born at 34 weeks of gestation or later.", "publicationTitle": "Frontiers in Pediatrics", "publisher": "", "place": "", "date": "2026", "volume": "14", "issue": "", "section": "", "partNumber": "", "partTitle": "", "pages": "1784451", "series": "", "seriesTitle": "", "seriesText": "", "journalAbbreviation": "Front Pediatr", "DOI": "10.3389/fped.2026.1784451", "citationKey": "", "url": "", "accessDate": "", "PMID": "41890301", "PMCID": "PMC13013305", "ISSN": "2296-2360", "archive": "", "archiveLocation": "", "shortTitle": "Associations between antenatal corticosteroids and neonatal morbidities in a prospective cohort", "language": "eng", "libraryCatalog": "PubMed", "callNumber": "", "rights": "", "extra": "", "tags": [ { "tag": "*corticosteroid" }, { "tag": "*dexamethasone" }, { "tag": "*gestational age" }, { "tag": "*newborn morbidity" }, { "tag": "adult" }, { "tag": "antenatal corticosteroids", "type": 1 }, { "tag": "article" }, { "tag": "asphyxia" }, { "tag": "cohort analysis" }, { "tag": "cohort study", "type": 1 }, { "tag": "complication" }, { "tag": "controlled study" }, { "tag": "dexamethasone", "type": 1 }, { "tag": "drug therapy" }, { "tag": "electronic health record" }, { "tag": "female" }, { "tag": "fetus lung maturation" }, { "tag": "gestational age", "type": 1 }, { "tag": "groups by age" }, { "tag": "human" }, { "tag": "infant" }, { "tag": "major clinical study" }, { "tag": "male" }, { "tag": "morbidity" }, { "tag": "multicenter study" }, { "tag": "neonatal morbidities", "type": 1 }, { "tag": "pregnancy" }, { "tag": "pregnant woman" }, { "tag": "premature labor" }, { "tag": "prospective study" }, { "tag": "special situation for pharmacovigilance" } ], "collections": [], "relations": { "dc:replaces": "http://zotero.org/groups/251615/items/6CTBWRVR" }, "dateAdded": "2026-04-07T19:56:54Z", "dateModified": "2026-04-07T20:20:10Z" } }, { "key": "73S7VB7K", "version": 12185, "library": { "type": "group", "id": 251615, "name": "CentreImage", "links": { "alternate": { "href": "https://www.zotero.org/groups/centreimage", "type": "text/html" } } }, "links": { "self": { "href": "https://api.zotero.org/groups/251615/items/73S7VB7K", "type": "application/json" }, "alternate": { "href": "https://www.zotero.org/groups/centreimage/items/73S7VB7K", "type": "text/html" } }, "meta": { "createdByUser": { "id": 14022664, "username": "TeodoraCHUSJ", "name": "", "links": { "alternate": { "href": "https://www.zotero.org/teodorachusj", "type": "text/html" } } }, "creatorSummary": "Wang et al.", "parsedDate": "2026", "numChildren": 1 }, "data": { "key": "73S7VB7K", "version": 12185, "itemType": "journalArticle", "title": "Analysis of copy number variations and candidate genes in recurrent pregnancy loss", "creators": [ { "creatorType": "author", "firstName": "Luming", "lastName": "Wang" }, { "creatorType": "author", "firstName": "Li", "lastName": "Yang" }, { "creatorType": "author", "firstName": "Suping", "lastName": "Li" }, { "creatorType": "author", "firstName": "Xiaodan", "lastName": "Liu" }, { "creatorType": "author", "firstName": "Ping", "lastName": "Tang" } ], "abstractNote": "BACKGROUND: Recurrent pregnancy loss (RPL) is often associated with genetic factors. This study investigates chromosomal abnormalities in RPL by analyzing copy number variations (CNVs) and single-nucleotide variants (SNVs).\nMETHODS: We conducted a retrospective analysis of 400 RPL patients, with 393 successfully analyzed using CNV-seq and single nucleotide polymorphism (SNP)-array after excluding maternal cell contamination (MCC). Additionally, 16 families with normal results underwent whole exome sequencing (WES).\nRESULTS: Among the patients, 187 (47.6%) showed normal results, while 206 (52.4%) exhibited abnormalities, including 152 aneuploidies (73.8%), 37 CNVs (18.0%), and 17 triploidies (8.3%). Statistical analysis revealed a significant increase in chromosomal abnormalities with advancing maternal age, but no significant differences in rates were observed before 24 weeks of pregnancy in patients with two or more miscarriages. We identified 28 pathogenic (P)/likely pathogenic (LP) CNVs and six P/LP SNVs, implicating 808 morbid genes. Enrichment analysis and protein-protein interaction (PPI) network construction revealed 69 key genes in critical pathways, with IL6, TNF, and ACTB as hub genes.\nDISCUSSION: These findings contribute to establishing genetic markers for RPL screening in the Chinese population, enhancing our understanding of miscarriage etiology and facilitating prenatal diagnosis.", "publicationTitle": "PeerJ", "publisher": "", "place": "", "date": "2026", "volume": "14", "issue": "", "section": "", "partNumber": "", "partTitle": "", "pages": "e20889", "series": "", "seriesTitle": "", "seriesText": "", "journalAbbreviation": "PeerJ", "DOI": "10.7717/peerj.20889", "citationKey": "", "url": "", "accessDate": "", "PMID": "41800136", "PMCID": "PMC12965170", "ISSN": "2167-8359", "archive": "", "archiveLocation": "", "shortTitle": "", "language": "eng", "libraryCatalog": "PubMed", "callNumber": "", "rights": "", "extra": "", "tags": [ { "tag": "*copy number variation" }, { "tag": "*gene" }, { "tag": "*spontaneous abortion" }, { "tag": "ABI 3500DX Genetic analyzer" }, { "tag": "ACTB protein/ec [Endogenous Compound]" }, { "tag": "Abortion, Habitual", "type": 1 }, { "tag": "Adult", "type": 1 }, { "tag": "CNV-seq", "type": 1 }, { "tag": "ChAS 4.3 software" }, { "tag": "Chromosome Aberrations", "type": 1 }, { "tag": "Copy number variation", "type": 1 }, { "tag": "CytoScan 750K Suite" }, { "tag": "DNA Copy Number Variations", "type": 1 }, { "tag": "DNA extraction" }, { "tag": "DNA purification kit" }, { "tag": "Exome Sequencing", "type": 1 }, { "tag": "Female", "type": 1 }, { "tag": "GATK software" }, { "tag": "Humans", "type": 1 }, { "tag": "KEGG" }, { "tag": "MGISEQ-2000 sequencer" }, { "tag": "Maternal Age", "type": 1 }, { "tag": "Polymorphism, Single Nucleotide", "type": 1 }, { "tag": "Pregnancy", "type": 1 }, { "tag": "QIAamp DNA Mini Kit" }, { "tag": "Recurrent pregnancy loss", "type": 1 }, { "tag": "Retrospective Studies", "type": 1 }, { "tag": "SNP-array", "type": 1 }, { "tag": "SPSS software Version 19" }, { "tag": "Whole exome sequencing", "type": 1 }, { "tag": "Young Adult", "type": 1 }, { "tag": "adult" }, { "tag": "aneuploidy" }, { "tag": "article" }, { "tag": "biomedical software" }, { "tag": "chromosome aberration" }, { "tag": "chromosome analysis" }, { "tag": "cohort analysis" }, { "tag": "col5a2 gene" }, { "tag": "controlled study" }, { "tag": "data analysis software" }, { "tag": "female" }, { "tag": "follow up" }, { "tag": "functional enrichment analysis" }, { "tag": "gene ontology" }, { "tag": "general software" }, { "tag": "genetic analyzer" }, { "tag": "genetic counseling" }, { "tag": "genetic marker" }, { "tag": "genetic screening" }, { "tag": "greb1l gene" }, { "tag": "heredity" }, { "tag": "human" }, { "tag": "interleukin 6/ec [Endogenous Compound]" }, { "tag": "karyotype" }, { "tag": "major clinical study" }, { "tag": "maternal age" }, { "tag": "microarray analysis" }, { "tag": "molecular biology" }, { "tag": "nucleic acid technique kit" }, { "tag": "peptides and proteins/ec [Endogenous Compound]" }, { "tag": "pregnancy" }, { "tag": "prenatal diagnosis" }, { "tag": "prospective study" }, { "tag": "protein protein interaction" }, { "tag": "retrospective study" }, { "tag": "single nucleotide polymorphism" }, { "tag": "transcription factor GATA 4/ec [Endogenous Compound]" }, { "tag": "tumor necrosis factor/ec [Endogenous Compound]" }, { "tag": "unclassified drug" }, { "tag": "whole exome sequencing" } ], "collections": [], "relations": { "dc:replaces": "http://zotero.org/groups/251615/items/GNHL3S6K" }, "dateAdded": "2026-04-07T19:56:54Z", "dateModified": "2026-04-07T20:20:09Z" } }, { "key": "ZG46D5EA", "version": 12179, "library": { "type": "group", "id": 251615, "name": "CentreImage", "links": { "alternate": { "href": "https://www.zotero.org/groups/centreimage", "type": "text/html" } } }, "links": { "self": { "href": "https://api.zotero.org/groups/251615/items/ZG46D5EA", "type": "application/json" }, "alternate": { "href": "https://www.zotero.org/groups/centreimage/items/ZG46D5EA", "type": "text/html" } }, "meta": { "createdByUser": { "id": 14022664, "username": "TeodoraCHUSJ", "name": "", "links": { "alternate": { "href": "https://www.zotero.org/teodorachusj", "type": "text/html" } } }, "creatorSummary": "Vilaplana et al.", "parsedDate": "2026-03-20", "numChildren": 1 }, "data": { "key": "ZG46D5EA", "version": 12179, "itemType": "journalArticle", "title": "Patient and public involvement in randomized trials of lifestyle intervention among pregnant women with obesity: An umbrella review", "creators": [ { "creatorType": "author", "firstName": "Elisabeth Garcia", "lastName": "Vilaplana" }, { "creatorType": "author", "firstName": "Andrea Vigaray", "lastName": "Galera" }, { "creatorType": "author", "firstName": "Carmen", "lastName": "Amezcua-Prieto" }, { "creatorType": "author", "firstName": "Khalid Saeed", "lastName": "Khan" }, { "creatorType": "author", "firstName": "Aurora", "lastName": "Bueno-Cavanillas" }, { "creatorType": "author", "firstName": "Begoña Martínez", "lastName": "de Tejada" }, { "creatorType": "author", "firstName": "Naomi", "lastName": "Cano-Ibáñez" } ], "abstractNote": "BACKGROUND: Obesity increases the risk of obstetric and neonatal complications, and adherence to lifestyle interventions during pregnancy presents a challenge. Patient and public involvement (PPI) in trials may foster a more patient-centered approach, potentially improving compliance with intervention and follow up.\nOBJECTIVE: To assess the extent of PPI in systematic reviews (SRs) and meta-analyses (MAs) focused on lifestyle interventions for pregnant women with obesity and its impact on compliance and follow-up rates of included randomized controlled trials (RCTs).\nSEARCH STRATEGY: Searches were conducted in PubMed, Scopus, Web of Science, and Embase using terms related to \"lifestyle\", \"obesity\", and \"pregnancy\", along with filters for SRs and MAs.\nSELECTION CRITERIA: SRs of RCTs, with or without MAs, published from 2013 to 2024, focusing on lifestyle interventions for pregnant women with obesity (BMI ≥30 [calculated as weight in kilograms divided by the square of height in meters]).\nDATA COLLECTION AND ANALYSIS: SR quality was assessed using AMSTAR 2. PPI reporting was evaluated using the GRIPP2 checklist and the ACTIVE framework. Compliance and follow-up rates were compared between RCTs with and without PPI.\nMAIN RESULTS: Eleven SRs, 10 with MAs (including 94 RCTs) were included. They were of low quality in 3/11 (27%) and critically low in 8/11 (73%). No SRs reported implementing PPI. Only 6/94 (10%) RCTs reported PPI, 2/29 (7%) directly after the introduction of GRIPP2 (2018) and 4/65 (6%) indirectly before its introduction (P = 0.79). PPI occurred during RCT methodology planning in 2/6 (33%), knowledge translation in 2/6 (33%), or both in 2/6 (33%). Compared with RCTs not reporting PPI (n = 94), the median intervention compliance rate in RCTs reporting PPI (n = 6) was higher (74% versus 68%, P = 0.637), and the follow-up rate was lower (78% versus 89%, P = 0.138), but the difference was not statistically significant. These findings warrant cautious interpretation given the limited number of RCTs reporting PPI.\nCONCLUSIONS: PPI remains scarce in both SRs and RCTs evaluating lifestyle interventions in pregnant women with obesity. Future research should integrate and clearly report PPI to strengthen the evaluation of lifestyle interventions in this population.", "publicationTitle": "International Journal of Gynaecology and Obstetrics: The Official Organ of the International Federation of Gynaecology and Obstetrics", "publisher": "", "place": "", "date": "2026-03-20", "volume": "", "issue": "", "section": "", "partNumber": "", "partTitle": "", "pages": "", "series": "", "seriesTitle": "", "seriesText": "", "journalAbbreviation": "Int J Gynaecol Obstet", "DOI": "10.1002/ijgo.70978", "citationKey": "", "url": "", "accessDate": "", "PMID": "41859876", "PMCID": "", "ISSN": "1879-3479", "archive": "", "archiveLocation": "", "shortTitle": "Patient and public involvement in randomized trials of lifestyle intervention among pregnant women with obesity", "language": "eng", "libraryCatalog": "PubMed", "callNumber": "", "rights": "", "extra": "", "tags": [ { "tag": "*lifestyle" }, { "tag": "*obesity" }, { "tag": "*pregnancy" }, { "tag": "*pregnant woman" }, { "tag": "*umbrella review" }, { "tag": "A Measurement Tool to Assess Systematic Reviews" }, { "tag": "adverse drug reaction" }, { "tag": "complication" }, { "tag": "drug therapy" }, { "tag": "follow up" }, { "tag": "human" }, { "tag": "lifestyle", "type": 1 }, { "tag": "meta analysis" }, { "tag": "obesity", "type": 1 }, { "tag": "patient and public involvement", "type": 1 }, { "tag": "patient selection" }, { "tag": "pregnancy", "type": 1 }, { "tag": "randomized controlled trial" }, { "tag": "review" }, { "tag": "side effect" }, { "tag": "systematic review" }, { "tag": "therapy" }, { "tag": "umbrella review", "type": 1 } ], "collections": [], "relations": { "dc:replaces": "http://zotero.org/groups/251615/items/MZLWS9EN" }, "dateAdded": "2026-04-07T19:56:54Z", "dateModified": "2026-04-07T20:20:08Z" } }, { "key": "3PZQEILI", "version": 12188, "library": { "type": "group", "id": 251615, "name": "CentreImage", "links": { "alternate": { "href": "https://www.zotero.org/groups/centreimage", "type": "text/html" } } }, "links": { "self": { "href": "https://api.zotero.org/groups/251615/items/3PZQEILI", "type": "application/json" }, "alternate": { "href": "https://www.zotero.org/groups/centreimage/items/3PZQEILI", "type": "text/html" } }, "meta": { "createdByUser": { "id": 14022664, "username": "TeodoraCHUSJ", "name": "", "links": { "alternate": { "href": "https://www.zotero.org/teodorachusj", "type": "text/html" } } }, "creatorSummary": "Uysal et al.", "parsedDate": "2026-03-04", "numChildren": 1 }, "data": { "key": "3PZQEILI", "version": 12188, "itemType": "journalArticle", "title": "Pregnancy outcomes following oral brivudine exposure: two case studies with long-term follow-up", "creators": [ { "creatorType": "author", "firstName": "Nusret", "lastName": "Uysal" }, { "creatorType": "author", "firstName": "Ismail", "lastName": "Yilmaz" }, { "creatorType": "author", "firstName": "Baris", "lastName": "Karadas" }, { "creatorType": "author", "firstName": "Nihal Olgac", "lastName": "Dundar" }, { "creatorType": "author", "firstName": "Yusuf Cem", "lastName": "Kaplan" } ], "abstractNote": "Brivudine is a thymidine analogue antiviral agent used in the treatment of herpes zoster; however, human data regarding its use during pregnancy are lacking. This report aims to describe pregnancy outcomes following oral brivudine exposure and to provide the first human clinical data on brivudine use during pregnancy. Two pregnant women exposed to oral brivudine during the first and second trimesters were referred for teratological risk assessment and followed with perinatal monitoring and postnatal clinical follow-up. Both pregnancies were continued with perinatological follow-up and resulted in the delivery of healthy infants without major congenital malformations. Postnatal follow-up identified mild allergic manifestations in one child and an isolated mild delay in the personal-social developmental domain in the other. These cases provide preliminary clinical data on brivudine exposure during pregnancy and contribute to the limited human data available.", "publicationTitle": "Naunyn-Schmiedeberg's Archives of Pharmacology", "publisher": "", "place": "", "date": "2026-03-04", "volume": "", "issue": "", "section": "", "partNumber": "", "partTitle": "", "pages": "", "series": "", "seriesTitle": "", "seriesText": "", "journalAbbreviation": "Naunyn Schmiedebergs Arch Pharmacol", "DOI": "10.1007/s00210-026-05154-7", "citationKey": "", "url": "", "accessDate": "", "PMID": "41776081", "PMCID": "", "ISSN": "1432-1912", "archive": "", "archiveLocation": "", "shortTitle": "Pregnancy outcomes following oral brivudine exposure", "language": "eng", "libraryCatalog": "PubMed", "callNumber": "", "rights": "", "extra": "", "tags": [ { "tag": "*5 (2 bromovinyl) 2' deoxyuridine" }, { "tag": "*case study" }, { "tag": "*congenital malformation" }, { "tag": "*follow up" }, { "tag": "*pregnancy" }, { "tag": "*pregnancy outcome" }, { "tag": "*teratology" }, { "tag": "Brivudine", "type": 1 }, { "tag": "Congenital abnormalities", "type": 1 }, { "tag": "Pregnancy", "type": 1 }, { "tag": "Teratology", "type": 1 }, { "tag": "adult" }, { "tag": "article" }, { "tag": "case report" }, { "tag": "child" }, { "tag": "clinical article" }, { "tag": "controlled study" }, { "tag": "doxribtimine" }, { "tag": "drug therapy" }, { "tag": "female" }, { "tag": "herpes zoster" }, { "tag": "human" }, { "tag": "hypersensitivity" }, { "tag": "infant" }, { "tag": "obstetric delivery" }, { "tag": "oral drug administration" }, { "tag": "pregnant woman" }, { "tag": "risk assessment" }, { "tag": "second trimester pregnancy" }, { "tag": "special situation for pharmacovigilance" }, { "tag": "therapy" } ], "collections": [], "relations": { "dc:replaces": "http://zotero.org/groups/251615/items/52BLZH2V" }, "dateAdded": "2026-04-07T19:56:54Z", "dateModified": "2026-04-07T20:20:07Z" } }, { "key": "VI9X9HGP", "version": 12246, "library": { "type": "group", "id": 251615, "name": "CentreImage", "links": { "alternate": { "href": "https://www.zotero.org/groups/centreimage", "type": "text/html" } } }, "links": { "self": { "href": "https://api.zotero.org/groups/251615/items/VI9X9HGP", "type": "application/json" }, "alternate": { "href": "https://www.zotero.org/groups/centreimage/items/VI9X9HGP", "type": "text/html" } }, "meta": { "createdByUser": { "id": 14022664, "username": "TeodoraCHUSJ", "name": "", "links": { "alternate": { "href": "https://www.zotero.org/teodorachusj", "type": "text/html" } } }, "creatorSummary": "Tolchinsky et al.", "parsedDate": "2026", "numChildren": 1 }, "data": { "key": "VI9X9HGP", "version": 12246, "itemType": "journalArticle", "title": "Another prospective study on the safety of ondansetron for nausea and vomiting of pregnancy: addressing ongoing concerns", "creators": [ { "creatorType": "author", "firstName": "Irina", "lastName": "Tolchinsky" }, { "creatorType": "author", "firstName": "Maayan", "lastName": "Beckinshtein" }, { "creatorType": "author", "firstName": "Elkana", "lastName": "Kohn" }, { "creatorType": "author", "firstName": "Rana", "lastName": "Cohen" }, { "creatorType": "author", "firstName": "Tal", "lastName": "De-Haan" }, { "creatorType": "author", "firstName": "Tomer", "lastName": "Ziv-Baran" }, { "creatorType": "author", "firstName": "David", "lastName": "Stepensky" }, { "creatorType": "author", "firstName": "Itai", "lastName": "Gueta" }, { "creatorType": "author", "firstName": "Matitiahu", "lastName": "Berkovitch" }, { "creatorType": "author", "firstName": "Maya", "lastName": "Berlin" } ], "abstractNote": "BACKGROUND: The safety of ondansetron for nausea and vomiting in pregnancy (NVP) remains a subject of ongoing debate, driven by conflicting study results and a disagreement between the European Medicines Agency (EMA) and the European Network of Teratology Information Services (ENTIS) regarding its potential fetal risks.\nOBJECTIVE: To assess the safety of using ondansetron for NVP and its possible association with major birth defects and neonatal outcomes.\nMETHODS: A prospective cohort study was conducted based on structured telephone follow-ups of women with NVP who contacted the NVP Helpline at a teratology information service (TIS) at the Shamir Medical Center between April 2014 and April 2018. Exposure and clinical characteristics were recorded during the initial consultation, and pregnancy and neonatal outcomes were ascertained after the estimated date of delivery using a validated questionnaire. Women treated with ondansetron formed the exposed group; controls did not receive ondansetron but could use other NVP therapies. Subgroup analyses explored the dose and frequency of use.\nRESULTS: The analysis included 260 women (137 exposed; 123 controls). Baseline characteristics were broadly comparable, except for higher NVP severity in the ondansetron group, reflected by higher PUQE scores (9.86 ± 2.66 vs. 8.59 ± 2.49; p = 0.001) and more frequent antacid use (p = 0.001). Live birth rates (95.6% vs. 94.3%) and birth weights did not differ between groups. No differences were found in neonatal complications. Major congenital malformations were comparable between groups (5.1% vs. 4.1%; p = 0.695), with no consistent pattern identified.\nCONCLUSION: In this prospective cohort, ondansetron exposure was not associated with increased risk of adverse neonatal outcomes or major congenital malformations. The sample size limits the detection of very rare outcomes, and larger studies remain warranted.", "publicationTitle": "Frontiers in Pharmacology", "publisher": "", "place": "", "date": "2026", "volume": "17", "issue": "", "section": "", "partNumber": "", "partTitle": "", "pages": "1783632", "series": "", "seriesTitle": "", "seriesText": "", "journalAbbreviation": "Front Pharmacol", "DOI": "10.3389/fphar.2026.1783632", "citationKey": "", "url": "", "accessDate": "", "PMID": "41883501", "PMCID": "PMC13008973", "ISSN": "1663-9812", "archive": "", "archiveLocation": "", "shortTitle": "Another prospective study on the safety of ondansetron for nausea and vomiting of pregnancy", "language": "eng", "libraryCatalog": "PubMed", "callNumber": "", "rights": "", "extra": "", "tags": [ { "tag": "*European Medicines Agency" }, { "tag": "*congenital malformation" }, { "tag": "*hyperemesis gravidarum" }, { "tag": "*information service" }, { "tag": "*morning sickness" }, { "tag": "*ondansetron" }, { "tag": "*pregnancy" }, { "tag": "*prospective study" }, { "tag": "*teratology" }, { "tag": "EMA (european medicines agency)", "type": 1 }, { "tag": "ENTIS (european network of teratology information services)", "type": 1 }, { "tag": "Germany" }, { "tag": "HG (hyperemesis gravidarum)", "type": 1 }, { "tag": "NVP (nausea and vomiting of pregnancy)", "type": 1 }, { "tag": "adult" }, { "tag": "adverse drug reaction" }, { "tag": "antacid agent" }, { "tag": "article" }, { "tag": "birth rate" }, { "tag": "birth weight" }, { "tag": "cohort analysis" }, { "tag": "complication" }, { "tag": "consultation" }, { "tag": "controlled study" }, { "tag": "female" }, { "tag": "fetus risk" }, { "tag": "follow up" }, { "tag": "human" }, { "tag": "live birth" }, { "tag": "major clinical study" }, { "tag": "major malformations", "type": 1 }, { "tag": "nausea and vomiting" }, { "tag": "ondansetron", "type": 1 }, { "tag": "questionnaire" } ], "collections": [ "34HIUU9M" ], "relations": { "dc:replaces": "http://zotero.org/groups/251615/items/ICHF63KZ" }, "dateAdded": "2026-04-07T19:56:54Z", "dateModified": "2026-04-07T20:20:06Z" } }, { "key": "XGZ26EGQ", "version": 12183, "library": { "type": "group", "id": 251615, "name": "CentreImage", "links": { "alternate": { "href": "https://www.zotero.org/groups/centreimage", "type": "text/html" } } }, "links": { "self": { "href": "https://api.zotero.org/groups/251615/items/XGZ26EGQ", "type": "application/json" }, "alternate": { "href": "https://www.zotero.org/groups/centreimage/items/XGZ26EGQ", "type": "text/html" } }, "meta": { "createdByUser": { "id": 14022664, "username": "TeodoraCHUSJ", "name": "", "links": { "alternate": { "href": "https://www.zotero.org/teodorachusj", "type": "text/html" } } }, "creatorSummary": "Maden et al.", "parsedDate": "2026-03-07", "numChildren": 1 }, "data": { "key": "XGZ26EGQ", "version": 12183, "itemType": "journalArticle", "title": "Vitamin D supplementation during pregnancy and offspring bone microarchitecture: A post hoc analysis of the MAVIDOS randomised controlled trial", "creators": [ { "creatorType": "author", "firstName": "Charlotte", "lastName": "Maden" }, { "creatorType": "author", "firstName": "Stefania", "lastName": "D'Angelo" }, { "creatorType": "author", "firstName": "Leo D.", "lastName": "Westbury" }, { "creatorType": "author", "firstName": "Elizabeth M.", "lastName": "Curtis" }, { "creatorType": "author", "firstName": "Sarah R.", "lastName": "Crozier" }, { "creatorType": "author", "firstName": "Keith M.", "lastName": "Godfrey" }, { "creatorType": "author", "firstName": "Kate A.", "lastName": "Ward" }, { "creatorType": "author", "firstName": "Cyrus", "lastName": "Cooper" }, { "creatorType": "author", "firstName": "Nicholas C.", "lastName": "Harvey" }, { "creatorType": "author", "firstName": "Rebecca J.", "lastName": "Moon" }, { "creatorType": "author", "name": "MAVIDOS Study Group" } ], "abstractNote": "BACKGROUND: Randomised trials have shown that pregnancy vitamin D supplementation results in greater offspring bone mineral density (BMD) in childhood. The effect of this intervention on bone microarchitecture, a further determinant of bone strength, and possible interactions with genetic variation in vitamin D metabolism, have not previously been investigated. We investigated these in a post hoc analysis of a randomised controlled trial.\nMETHODS: MAVIDOS was a randomised placebo-controlled trial of 1000 IU/day cholecalciferol from 14 to 17 weeks' gestation until delivery. Offspring tibial bone microarchitecture was assessed at age 6-7 years using high resolution peripheral quantitative computed tomography (HR-pQCT; Stratec Xtreme CTII). Maternal and child genotype at four single nucleotide polymorphisms (SNPs) [rs12785878 (DHCR7), rs10741657 (CYP2R1), rs6013897 (CYP24A1), rs2282679 (GC)] was determined using serum samples. Differences in bone microarchitecture by randomisation were assessed using linear regression, and additionally across clusters of bone microarchitecture phenotypes generated using cluster analysis approaches.\nRESULTS: 222 children (placebo n = 110, cholecalciferol n = 112) were included. No significant differences in cross-sectional area, cortical thickness or porosity, trabecular thickness or number, or volumetric BMD (total, cortical or trabecular) were found using linear regression, and there was no interaction with either maternal or offspring SNP genetic variants. Three phenotypic bone clusters were generated. Differences in child anthropometry were evident across clusters, but the proportion of mothers randomised to cholecalciferol was similar across the clusters (p = 1.0).\nCONCLUSION: In this subset of children born to mothers participating in a trial of vitamin D supplementation in pregnancy, no effect of the supplementation on tibial microarchitecture was observed.", "publicationTitle": "Bone", "publisher": "", "place": "", "date": "2026-03-07", "volume": "207", "issue": "", "section": "", "partNumber": "", "partTitle": "", "pages": "117843", "series": "", "seriesTitle": "", "seriesText": "", "journalAbbreviation": "Bone", "DOI": "10.1016/j.bone.2026.117843", "citationKey": "", "url": "", "accessDate": "", "PMID": "41802552", "PMCID": "", "ISSN": "1873-2763", "archive": "", "archiveLocation": "", "shortTitle": "Vitamin D supplementation during pregnancy and offspring bone microarchitecture", "language": "eng", "libraryCatalog": "PubMed", "callNumber": "", "rights": "", "extra": "", "tags": [ { "tag": "*bone microarchitecture" }, { "tag": "*colecalciferol/cm [Drug Comparison]" }, { "tag": "*colecalciferol/po [Oral Drug Administration]" }, { "tag": "*colecalciferol/pv [Special Situation for Pharmacovigilance]" }, { "tag": "*colecalciferol/tm [Unexpected Outcome of Drug Treatment]" }, { "tag": "*pregnancy" }, { "tag": "*progeny" }, { "tag": "*vitamin supplementation" }, { "tag": "Bone microarchitecture", "type": 1 }, { "tag": "Bone mineral density", "type": 1 }, { "tag": "CT scanner" }, { "tag": "CYP24A1 gene" }, { "tag": "CYP2R1 gene" }, { "tag": "Cholecalciferol", "type": 1 }, { "tag": "High resolution peripheral quantitative computed tomography (HR-pQCT)", "type": 1 }, { "tag": "Stratec Xtreme" }, { "tag": "adult" }, { "tag": "anthropometry" }, { "tag": "article" }, { "tag": "blood sampling" }, { "tag": "bone density" }, { "tag": "bone strength" }, { "tag": "child" }, { "tag": "cluster analysis" }, { "tag": "computer assisted tomography" }, { "tag": "cortical thickness (bone)" }, { "tag": "dhcr7 gene" }, { "tag": "female" }, { "tag": "gene" }, { "tag": "genetic variation" }, { "tag": "genotype" }, { "tag": "gestational age" }, { "tag": "human" }, { "tag": "linear regression analysis" }, { "tag": "normal human" }, { "tag": "obstetric delivery" }, { "tag": "phenotype" }, { "tag": "placebo" }, { "tag": "porosity" }, { "tag": "post hoc analysis" }, { "tag": "pregnancy", "type": 1 }, { "tag": "preschool child" }, { "tag": "randomized controlled trial (topic)" }, { "tag": "school child" }, { "tag": "single nucleotide polymorphism" }, { "tag": "trabecular thickness" }, { "tag": "vitamin D metabolism" }, { "tag": "vitamin D/ec [Endogenous Compound]" }, { "tag": "volumetry" } ], "collections": [], "relations": { "dc:replaces": "http://zotero.org/groups/251615/items/DLXVPQRT" }, "dateAdded": "2026-04-07T19:56:54Z", "dateModified": "2026-04-07T20:20:05Z" } }, { "key": "HUFMMQ3G", "version": 12180, "library": { "type": "group", "id": 251615, "name": "CentreImage", "links": { "alternate": { "href": "https://www.zotero.org/groups/centreimage", "type": "text/html" } } }, "links": { "self": { "href": "https://api.zotero.org/groups/251615/items/HUFMMQ3G", "type": "application/json" }, "alternate": { "href": "https://www.zotero.org/groups/centreimage/items/HUFMMQ3G", "type": "text/html" } }, "meta": { "createdByUser": { "id": 14022664, "username": "TeodoraCHUSJ", "name": "", "links": { "alternate": { "href": "https://www.zotero.org/teodorachusj", "type": "text/html" } } }, "creatorSummary": "Liu et al.", "parsedDate": "2026-03", "numChildren": 1 }, "data": { "key": "HUFMMQ3G", "version": 12180, "itemType": "journalArticle", "title": "Impact of CYP2D6 Metabolizer Status on Ondansetron Efficacy in Early Pregnancy Induced Nausea and Vomiting: A Case Control Study", "creators": [ { "creatorType": "author", "firstName": "Michelle", "lastName": "Liu" }, { "creatorType": "author", "firstName": "Megan M.", "lastName": "Shuey" }, { "creatorType": "author", "firstName": "Sabrina E.", "lastName": "Holley" }, { "creatorType": "author", "firstName": "Darlene F.", "lastName": "Fountain" }, { "creatorType": "author", "firstName": "James", "lastName": "Jaworski" }, { "creatorType": "author", "firstName": "Carol", "lastName": "Griffin" }, { "creatorType": "author", "firstName": "Jeewoo", "lastName": "Kim" }, { "creatorType": "author", "firstName": "Melissa", "lastName": "Stec" }, { "creatorType": "author", "firstName": "Sudeep D.", "lastName": "Sunthankar" }, { "creatorType": "author", "firstName": "Henry H.", "lastName": "Ong" }, { "creatorType": "author", "firstName": "Srushti", "lastName": "Gangireddy" }, { "creatorType": "author", "firstName": "Wei-Qi", "lastName": "Wei" }, { "creatorType": "author", "firstName": "Andrea", "lastName": "Gaedigk" }, { "creatorType": "author", "firstName": "Digna R.", "lastName": "Velez Edwards" }, { "creatorType": "author", "firstName": "Vivian K.", "lastName": "Kawai" } ], "abstractNote": "Real-world data investigating CYP2D6 on the efficacy of ondansetron for nausea and vomiting in pregnancy (NVP) is lacking. Evidence shows CYP2D6 ultrarapid metabolizers are at risk of ondansetron nonresponse due to increased metabolism. We conducted a retrospective cohort study of early pregnant patients on ondansetron for NVP. Genotype data for 11 CYP2D6 variants and copy number variations were translated into activity score (AS) and metabolizer status: poor (PM), intermediate (IM), normal (NM), and ultrarapid (UM) metabolizers. A total of 264 women met inclusion/exclusion criteria (99 cases and 165 controls). Multivariate regression analyses of metabolizer status and AS were adjusted for significant independent variables. The majority had gravidity of two, singleton pregnancy, a median age of 28 (interquartile range [IQR] 24-31) years, and identified as White (65.5%). Ondansetron dose was similar among the cohort and half received other antiemetics simultaneously. Clinical characteristics between cases and controls did not differ except for gestational age (8 vs. 10 weeks, p = 0.004) and primigravida rate (45.5% vs. 32.7%, p = 0.017). When adjusted for covariates, metabolizer status was not associated with response. UM/NM had non-significantly higher risk of nonresponse (odds ratio [OR] 1.53, 95% confidence interval [CI], 0.88-2.66) compared to PM/IM. Similar trends were observed with higher CYP2D6 AS showing increased risk of nonresponse (OR 1.22, 95% CI [0.81-1.85]). This study found no significant differences in ondansetron response in early pregnancy based on CYP2D6 UM/NM versus PM/IM and AS. Additional prospective investigations are necessary to confirm the CYP2D6 effect on ondansetron efficacy in pregnant patients.", "publicationTitle": "Clinical and Translational Science", "publisher": "", "place": "", "date": "2026-03", "volume": "19", "issue": "3", "section": "", "partNumber": "", "partTitle": "", "pages": "e70523", "series": "", "seriesTitle": "", "seriesText": "", "journalAbbreviation": "Clin Transl Sci", "DOI": "10.1111/cts.70523", "citationKey": "", "url": "", "accessDate": "", "PMID": "41820792", "PMCID": "", "ISSN": "1752-8062", "archive": "", "archiveLocation": "", "shortTitle": "Impact of CYP2D6 Metabolizer Status on Ondansetron Efficacy in Early Pregnancy Induced Nausea and Vomiting", "language": "eng", "libraryCatalog": "PubMed", "callNumber": "", "rights": "", "extra": "", "tags": [ { "tag": "*cytochrome P450 2D6/ec [Endogenous Compound]" }, { "tag": "*drug efficacy" }, { "tag": "*first trimester pregnancy" }, { "tag": "*nausea and vomiting/dt [Drug Therapy]" }, { "tag": "*ondansetron/dt [Drug Therapy]" }, { "tag": "*ondansetron/po [Oral Drug Administration]" }, { "tag": "Adult", "type": 1 }, { "tag": "Antiemetics", "type": 1 }, { "tag": "CYP2D6", "type": 1 }, { "tag": "Case-Control Studies", "type": 1 }, { "tag": "Cytochrome P-450 CYP2D6", "type": 1 }, { "tag": "DNA extraction" }, { "tag": "Female", "type": 1 }, { "tag": "Genotype", "type": 1 }, { "tag": "Humans", "type": 1 }, { "tag": "Morning Sickness", "type": 1 }, { "tag": "Nausea", "type": 1 }, { "tag": "Ondansetron", "type": 1 }, { "tag": "Pregnancy", "type": 1 }, { "tag": "R Studio version 4.1" }, { "tag": "Retrospective Studies", "type": 1 }, { "tag": "STATA software program version 17" }, { "tag": "Treatment Outcome", "type": 1 }, { "tag": "Vomiting", "type": 1 }, { "tag": "Young Adult", "type": 1 }, { "tag": "adult" }, { "tag": "article" }, { "tag": "case control study" }, { "tag": "chlorpromazine" }, { "tag": "clinical feature" }, { "tag": "cohort analysis" }, { "tag": "controlled study" }, { "tag": "data analysis software" }, { "tag": "genotyping" }, { "tag": "gestational age" }, { "tag": "hospital admission" }, { "tag": "human" }, { "tag": "major clinical study" }, { "tag": "metoclopramide" }, { "tag": "multivariate logistic regression analysis" }, { "tag": "nausea and vomiting", "type": 1 }, { "tag": "personalized medicine" }, { "tag": "pharmacogenetics" }, { "tag": "phenotype" }, { "tag": "precision medicine", "type": 1 }, { "tag": "pregnancy" }, { "tag": "pregnant woman" }, { "tag": "promethazine" }, { "tag": "pyridoxine" }, { "tag": "retrospective study" }, { "tag": "single nucleotide polymorphism" }, { "tag": "women", "type": 1 } ], "collections": [], "relations": { "dc:replaces": "http://zotero.org/groups/251615/items/QX59JIPD" }, "dateAdded": "2026-04-07T19:56:54Z", "dateModified": "2026-04-07T20:20:04Z" } }, { "key": "FVR4Y39Z", "version": 12178, "library": { "type": "group", "id": 251615, "name": "CentreImage", "links": { "alternate": { "href": "https://www.zotero.org/groups/centreimage", "type": "text/html" } } }, "links": { "self": { "href": "https://api.zotero.org/groups/251615/items/FVR4Y39Z", "type": "application/json" }, "alternate": { "href": "https://www.zotero.org/groups/centreimage/items/FVR4Y39Z", "type": "text/html" } }, "meta": { "createdByUser": { "id": 14022664, "username": "TeodoraCHUSJ", "name": "", "links": { "alternate": { "href": "https://www.zotero.org/teodorachusj", "type": "text/html" } } }, "creatorSummary": "Kraft et al.", "parsedDate": "2026-03-20", "numChildren": 1 }, "data": { "key": "FVR4Y39Z", "version": 12178, "itemType": "journalArticle", "title": "Penicillin Allergy Delabeling Can and Should Be Performed in Pregnant Patients: A Work Group Report of the AAAAI Women's Health in Allergy and Immunology and Adverse Reaction to Drugs, Biologics and Committees", "creators": [ { "creatorType": "author", "firstName": "Monica T.", "lastName": "Kraft" }, { "creatorType": "author", "firstName": "Victoria T.", "lastName": "Nguyen" }, { "creatorType": "author", "firstName": "Nonie", "lastName": "Arora" }, { "creatorType": "author", "firstName": "Aleena", "lastName": "Banerji" }, { "creatorType": "author", "firstName": "Sindhura", "lastName": "Bandi" }, { "creatorType": "author", "firstName": "Sergio E.", "lastName": "Chiarella" }, { "creatorType": "author", "firstName": "Mildred", "lastName": "Kwan" }, { "creatorType": "author", "firstName": "Jennifer", "lastName": "Namazy" }, { "creatorType": "author", "firstName": "Anil", "lastName": "Nanda" }, { "creatorType": "author", "firstName": "Katherine", "lastName": "Strafford" }, { "creatorType": "author", "firstName": "Anita", "lastName": "Wasan" }, { "creatorType": "author", "firstName": "Anna R.", "lastName": "Wolfson" } ], "abstractNote": "Penicillin allergy is frequently reported yet rarely confirmed in pregnant women, similar to the general population. Historically, there has been hesitation to perform penicillin allergy testing in pregnant patients due to perceived risk to the patient and fetus in the event of an allergic reaction. Given the multiple clinical indications for penicillin in pregnancy and delivery, there are also risks of using non-first-line antibiotics; thus clarity is needed regarding the safety of undergoing penicillin allergy testing during pregnancy. A workgroup subcommittee of members from the American Academy of Allergy, Asthma & Immunology committees on Women's Health in Allergy/Immunology and Adverse Reactions to Drugs, Biologics, and Vaccines was convened, and a survey of current allergist practices as well as a scoping review of the literature was conducted. Although survey respondents reported mixed comfort with testing, evidence from numerous recent studies representing hundreds of pregnant patients demonstrates that penicillin allergy testing can be safely performed via an oral challenge with or without preceding skin testing. To implement this testing in clinical practice, allergists and immunologists can learn from the clinical experience of numerous institutions that have reported a successful approach to offering definitive allergy evaluation in this population.", "publicationTitle": "The Journal of Allergy and Clinical Immunology. In Practice", "publisher": "", "place": "", "date": "2026-03-20", "volume": "", "issue": "", "section": "", "partNumber": "", "partTitle": "", "pages": "S2213-2198(26)00149-2", "series": "", "seriesTitle": "", "seriesText": "", "journalAbbreviation": "J Allergy Clin Immunol Pract", "DOI": "10.1016/j.jaip.2026.01.046", "citationKey": "", "url": "", "accessDate": "", "PMID": "41860518", "PMCID": "", "ISSN": "2213-2201", "archive": "", "archiveLocation": "", "shortTitle": "Penicillin Allergy Delabeling Can and Should Be Performed in Pregnant Patients", "language": "eng", "libraryCatalog": "PubMed", "callNumber": "", "rights": "", "extra": "", "tags": [ { "tag": "*allergy" }, { "tag": "*allergy test" }, { "tag": "*biological product" }, { "tag": "*penicillin allergy" }, { "tag": "*penicillin derivative" }, { "tag": "*pregnancy" }, { "tag": "*women's health" }, { "tag": "Allergy testing", "type": 1 }, { "tag": "Penicillin allergy", "type": 1 }, { "tag": "Pregnancy", "type": 1 }, { "tag": "Pregnant", "type": 1 }, { "tag": "adverse drug reaction" }, { "tag": "antibiotic agent" }, { "tag": "article" }, { "tag": "case report" }, { "tag": "clinical practice" }, { "tag": "drug therapy" }, { "tag": "female" }, { "tag": "human" }, { "tag": "hypersensitivity" }, { "tag": "immunologist" }, { "tag": "obstetric delivery" }, { "tag": "pregnant woman" }, { "tag": "scoping review" }, { "tag": "side effect" }, { "tag": "skin test" } ], "collections": [], "relations": { "dc:replaces": "http://zotero.org/groups/251615/items/84LHBAIA" }, "dateAdded": "2026-04-07T19:56:54Z", "dateModified": "2026-04-07T20:20:03Z" } }, { "key": "E8PH6RE7", "version": 12192, "library": { "type": "group", "id": 251615, "name": "CentreImage", "links": { "alternate": { "href": "https://www.zotero.org/groups/centreimage", "type": "text/html" } } }, "links": { "self": { "href": "https://api.zotero.org/groups/251615/items/E8PH6RE7", "type": "application/json" }, "alternate": { "href": "https://www.zotero.org/groups/centreimage/items/E8PH6RE7", "type": "text/html" } }, "meta": { "createdByUser": { "id": 14022664, "username": "TeodoraCHUSJ", "name": "", "links": { "alternate": { "href": "https://www.zotero.org/teodorachusj", "type": "text/html" } } }, "creatorSummary": "Kim et al.", "parsedDate": "2026-03-07", "numChildren": 1 }, "data": { "key": "E8PH6RE7", "version": 12192, "itemType": "journalArticle", "title": "Antipsychotic Discontinuation and Re-initiation in Pregnant Women With Schizophrenia: A Retrospective Cohort Study From South Korea", "creators": [ { "creatorType": "author", "firstName": "Jiyeon", "lastName": "Kim" }, { "creatorType": "author", "firstName": "Julia", "lastName": "Kaminska" }, { "creatorType": "author", "firstName": "Ye-Jee", "lastName": "Kim" }, { "creatorType": "author", "firstName": "Sung Woo", "lastName": "Joo" }, { "creatorType": "author", "firstName": "Bo Ram", "lastName": "Yang" } ], "abstractNote": "BACKGROUND AND HYPOTHESIS: Pregnant women with schizophrenia are more likely to discontinue treatment, which could trigger a relapse of symptoms. However, data on patterns and risk factors related to antipsychotic discontinuation and re-initiation in Asian pregnant women are insufficient.\nSTUDY DESIGN: We conducted a retrospective cohort study using a nationwide Korean database. The pregnancy group included women who had received antipsychotics before pregnancy and was matched 1:2 with a non-pregnancy group. Using Kaplan-Meier curves, we assessed discontinuation patterns during pregnancy and re-initiation patterns among those who discontinued treatment within the first trimester. A Cox proportional hazards regression analysis was used to examine factors associated with first-trimester discontinuation and re-initiation among those who discontinued during this period.\nSTUDY RESULTS: Pregnant women (n = 2066) had a significantly higher risk of discontinuation than did non-pregnant women (adjusted hazard ratio 3.09; 95% confidence interval 2.85-3.34). Within the first trimester, 67.5% of pregnant women (n = 1394) discontinued antipsychotic use. Women aged 25-29 years were more likely to discontinue (1.25; 1.07-1.47). Among first-trimester discontinuers, 35.2% (n = 491) re-initiated treatment before delivery. A longer duration of antipsychotic use (1.60; 1.06-2.42) and higher daily doses (2.47; 1.76-3.45) were associated with re-initiation of antipsychotics.\nCONCLUSIONS: We revealed that most pregnant women discontinued schizophrenia treatment, but those using higher cumulative doses had a higher likelihood of re-initiation. Our findings imply that treatment decisions for pregnant women should consider various clinical factors, including the history of prescriptions and obstetric characteristics. Moreover, these patients require close monitoring after discontinuation.", "publicationTitle": "Schizophrenia Bulletin", "publisher": "", "place": "", "date": "2026-03-07", "volume": "52", "issue": "2", "section": "", "partNumber": "", "partTitle": "", "pages": "sbaf077", "series": "", "seriesTitle": "", "seriesText": "", "journalAbbreviation": "Schizophr Bull", "DOI": "10.1093/schbul/sbaf077", "citationKey": "", "url": "", "accessDate": "", "PMID": "40433781", "PMCID": "PMC12996872", "ISSN": "1745-1701", "archive": "", "archiveLocation": "", "shortTitle": "Antipsychotic Discontinuation and Re-initiation in Pregnant Women With Schizophrenia", "language": "eng", "libraryCatalog": "PubMed", "callNumber": "", "rights": "", "extra": "", "tags": [ { "tag": "*South Korea" }, { "tag": "*neuroleptic agent" }, { "tag": "*pregnancy" }, { "tag": "*pregnant woman" }, { "tag": "*schizophrenia" }, { "tag": "Adult", "type": 1 }, { "tag": "Antipsychotic Agents", "type": 1 }, { "tag": "Female", "type": 1 }, { "tag": "Humans", "type": 1 }, { "tag": "Korean (people)" }, { "tag": "Pregnancy", "type": 1 }, { "tag": "Pregnancy Complications", "type": 1 }, { "tag": "Pregnancy Trimester, First", "type": 1 }, { "tag": "Republic of Korea", "type": 1 }, { "tag": "Retrospective Studies", "type": 1 }, { "tag": "Schizophrenia", "type": 1 }, { "tag": "Young Adult", "type": 1 }, { "tag": "adult" }, { "tag": "antipsychotics", "type": 1 }, { "tag": "article" }, { "tag": "cohort analysis" }, { "tag": "controlled study" }, { "tag": "discontinuation", "type": 1 }, { "tag": "drug therapy" }, { "tag": "female" }, { "tag": "first trimester pregnancy" }, { "tag": "human" }, { "tag": "major clinical study" }, { "tag": "obstetric delivery" }, { "tag": "pregnancy", "type": 1 }, { "tag": "prescription" }, { "tag": "re-initiation", "type": 1 }, { "tag": "relapse" }, { "tag": "retrospective study" }, { "tag": "risk factor" }, { "tag": "schizophrenia", "type": 1 } ], "collections": [], "relations": { "dc:replaces": "http://zotero.org/groups/251615/items/EM3XPELU" }, "dateAdded": "2026-04-07T19:56:54Z", "dateModified": "2026-04-07T20:20:01Z" } }, { "key": "Y67QCLSC", "version": 12182, "library": { "type": "group", "id": 251615, "name": "CentreImage", "links": { "alternate": { "href": "https://www.zotero.org/groups/centreimage", "type": "text/html" } } }, "links": { "self": { "href": "https://api.zotero.org/groups/251615/items/Y67QCLSC", "type": "application/json" }, "alternate": { "href": "https://www.zotero.org/groups/centreimage/items/Y67QCLSC", "type": "text/html" } }, "meta": { "createdByUser": { "id": 14022664, "username": "TeodoraCHUSJ", "name": "", "links": { "alternate": { "href": "https://www.zotero.org/teodorachusj", "type": "text/html" } } }, "creatorSummary": "Gomes et al.", "parsedDate": "2026", "numChildren": 1 }, "data": { "key": "Y67QCLSC", "version": 12182, "itemType": "journalArticle", "title": "Evolving antimicrobial resistance patterns in group B streptococci: A five-year study in a high-risk pregnancy referral center in northeastern Brazil", "creators": [ { "creatorType": "author", "firstName": "Jorhanna Isabelle Araújo de Brito", "lastName": "Gomes" }, { "creatorType": "author", "firstName": "Suellen Bernardo de", "lastName": "Queiroz" }, { "creatorType": "author", "firstName": "Carlos Gabriel Andrade", "lastName": "Barbosa" }, { "creatorType": "author", "firstName": "Larissa Rodrigues Santos", "lastName": "Silva" }, { "creatorType": "author", "firstName": "Patrícia Urquiza", "lastName": "Lundgren" }, { "creatorType": "author", "firstName": "Eduardo Sergio Soares", "lastName": "Sousa" }, { "creatorType": "author", "firstName": "Eloiza Helena", "lastName": "Campana" }, { "creatorType": "author", "firstName": "Vinicius Pietta", "lastName": "Perez" } ], "abstractNote": "BACKGROUND: Streptococcus agalactiae (commonly referred to as group B streptococci [GBS]) is a leading cause of neonatal infection. Surveillance of colonization in pregnant women and the use of intrapartum antibiotic prophylaxis (IAP) are the primary strategies for preventing early-onset GBS disease. The increasing rate of antibiotic resistance among GBS isolates is a concern for the effectiveness of IAP. Our study aimed to evaluate the prevalence of GBS colonization and characterize antimicrobial resistance patterns over a five-year period in a high-risk pregnancy referral center in Northeastern Brazil.\nMETHODS: This study was conducted from 2020 to 2024 and included pregnant women at 35-37-week gestation. GBS isolates from anal-vaginal swabs were identified and tested for susceptibility to penicillin or ampicillin, clindamycin, erythromycin, levofloxacin, and tetracycline. Isolates stored from 2021 to 2024 were further analyzed for the resistance genes mef(A), erm(A/TR), erm(B), tet(M), and tet(O).\nRESULTS: Of 1469 anal-vaginal samples, the overall GBS colonization rate was 12%. All isolates were susceptible to either penicillin or ampicillin. The respective resistance rates for erythromycin, clindamycin, levofloxacin, and tetracycline were 23.6%, 9.3%, 5.4%, and 82.3%. The main determinant among macrolide-resistant isolates was mef(A), and tet(M) was the most frequent tetracycline resistance gene. Furthermore, we found that erythromycin resistance increased consistently over the five years, signaling a potential impact on clindamycin efficacy due to erm genes.\nCONCLUSIONS: Beta-lactams (penicillin and ampicillin) remained effective for IAP in northeastern Brazil during the study period. However, high and increasing resistance to other antibiotic classes reinforces the need for maternal GBS surveillance and ongoing antimicrobial resistance monitoring.", "publicationTitle": "Revista Da Sociedade Brasileira De Medicina Tropical", "publisher": "", "place": "", "date": "2026", "volume": "59", "issue": "", "section": "", "partNumber": "", "partTitle": "", "pages": "e0259", "series": "", "seriesTitle": "", "seriesText": "", "journalAbbreviation": "Rev Soc Bras Med Trop", "DOI": "10.1590/0037-8682-0259-2025", "citationKey": "", "url": "", "accessDate": "", "PMID": "41810606", "PMCID": "PMC12971026", "ISSN": "1678-9849", "archive": "", "archiveLocation": "", "shortTitle": "Evolving antimicrobial resistance patterns in group B streptococci", "language": "eng", "libraryCatalog": "PubMed", "callNumber": "", "rights": "", "extra": "", "tags": [ { "tag": "*Streptococcus agalactiae" }, { "tag": "*antibiotic resistance" }, { "tag": "*high risk pregnancy" }, { "tag": "*patient referral" }, { "tag": "Adult", "type": 1 }, { "tag": "Anti-Bacterial Agents", "type": 1 }, { "tag": "Brazil", "type": 1 }, { "tag": "Drug Resistance, Bacterial", "type": 1 }, { "tag": "Female", "type": 1 }, { "tag": "Humans", "type": 1 }, { "tag": "Microbial Sensitivity Tests", "type": 1 }, { "tag": "Pregnancy", "type": 1 }, { "tag": "Pregnancy Complications, Infectious", "type": 1 }, { "tag": "Prevalence", "type": 1 }, { "tag": "SPSS version 20.0 for Mac OS" }, { "tag": "Streptococcal Infections", "type": 1 }, { "tag": "Streptococcus agalactiae", "type": 1 }, { "tag": "Vagina", "type": 1 }, { "tag": "ampicillin" }, { "tag": "antibiotic prophylaxis" }, { "tag": "antibiotic sensitivity" }, { "tag": "article" }, { "tag": "bacterial colonization" }, { "tag": "bacterium identification" }, { "tag": "bacterium isolate" }, { "tag": "clindamycin" }, { "tag": "cross-sectional study" }, { "tag": "data analysis software" }, { "tag": "disk diffusion" }, { "tag": "erythromycin" }, { "tag": "female" }, { "tag": "genotype" }, { "tag": "gestational age" }, { "tag": "group B streptococcal infection" }, { "tag": "human" }, { "tag": "levofloxacin" }, { "tag": "macrolide" }, { "tag": "major clinical study" }, { "tag": "newborn infection" }, { "tag": "nonhuman" }, { "tag": "observational study" }, { "tag": "penicillin derivative" }, { "tag": "polymerase chain reaction" }, { "tag": "pregnant woman" }, { "tag": "prevalence" }, { "tag": "tetracycline" }, { "tag": "vagina smear" } ], "collections": [], "relations": { "dc:replaces": "http://zotero.org/groups/251615/items/Z9ARPXAM" }, "dateAdded": "2026-04-07T19:56:54Z", "dateModified": "2026-04-07T20:20:00Z" } }, { "key": "D8NL3DW4", "version": 12187, "library": { "type": "group", "id": 251615, "name": "CentreImage", "links": { "alternate": { "href": "https://www.zotero.org/groups/centreimage", "type": "text/html" } } }, "links": { "self": { "href": "https://api.zotero.org/groups/251615/items/D8NL3DW4", "type": "application/json" }, "alternate": { "href": "https://www.zotero.org/groups/centreimage/items/D8NL3DW4", "type": "text/html" } }, "meta": { "createdByUser": { "id": 14022664, "username": "TeodoraCHUSJ", "name": "", "links": { "alternate": { "href": "https://www.zotero.org/teodorachusj", "type": "text/html" } } }, "creatorSummary": "Girma et al.", "parsedDate": "2026-03-05", "numChildren": 1 }, "data": { "key": "D8NL3DW4", "version": 12187, "itemType": "journalArticle", "title": "The critical gap in prevention: knowledge of periconception folic acid supplementation and its predictors among pregnant women in Ethiopia", "creators": [ { "creatorType": "author", "firstName": "Timsel", "lastName": "Girma" }, { "creatorType": "author", "firstName": "Desalegn Tsegaw", "lastName": "Hibstu" }, { "creatorType": "author", "firstName": "Befikadu", "lastName": "Amare" }, { "creatorType": "author", "firstName": "Geracho", "lastName": "Garolla" } ], "abstractNote": "INTRODUCTION: Folic acid deficiency is the most common pregnancy-related micronutrient deficiency, leading to fetal neural tube defects (NTDs). Periconceptional folic acid supplementation is highly effective in reducing NTDs by 72%-86%. However, awareness of this essential prevention method remains limited in lower-income countries, contributing to a high rate of preventable birth defects. Therefore, this study aims to evaluate the knowledge and factors associated with periconceptional folic acid supplementation among pregnant women attending the Antenatal care clinic at Dilla University Teaching Hospital in 2024.\nMETHOD: This institution-based cross-sectional study was conducted at Dilla University Teaching Hospital from January to December 2024. A systematic random sampling technique was used to enroll 337 eligible pregnant mothers attending Antenatal Care. Bivariate and multiple logistic regression analyses were performed to identify associated factors. The strength of association was reported using the Adjusted Odds Ratio (AOR) with a Confidence Interval (CI), with p-values considered statistically significant.\nRESULT: Only 8.9% (95% CI: 5.85%-11.96%) of pregnant mothers demonstrated good knowledge of periconceptional folic acid supplementation. Factors significantly associated with improved knowledge included higher education (AOR 5.13), current family planning use (AOR 4.06), having a planned pregnancy (AOR 3.59), being in the 26–30 age group (AOR 2.33), and employment status (AOR 1.63).\nCONCLUSION: Knowledge of periconceptional folic acid supplementation is extremely poor (8.9%) among pregnant women in the study area. Factors like higher education, family planning use, and planned pregnancy are strong determinants of awareness. There is an urgent need to implement targeted health education programs integrated within Antenatal Care and Family Planning services to improve knowledge and reduce the incidence of preventable NTDs.\nSUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s40748-026-00254-x.", "publicationTitle": "Maternal Health, Neonatology and Perinatology", "publisher": "", "place": "", "date": "2026-03-05", "volume": "12", "issue": "1", "section": "", "partNumber": "", "partTitle": "", "pages": "9", "series": "", "seriesTitle": "", "seriesText": "", "journalAbbreviation": "Matern Health Neonatol Perinatol", "DOI": "10.1186/s40748-026-00254-x", "citationKey": "", "url": "", "accessDate": "", "PMID": "41787573", "PMCID": "PMC12961768", "ISSN": "2054-958X", "archive": "", "archiveLocation": "", "shortTitle": "The critical gap in prevention", "language": "eng", "libraryCatalog": "PubMed", "callNumber": "", "rights": "", "extra": "", "tags": [ { "tag": "*Ethiopia" }, { "tag": "*folic acid" }, { "tag": "*knowledge" }, { "tag": "*maternal care" }, { "tag": "*pregnancy" }, { "tag": "*pregnant woman" }, { "tag": "*prenatal care" }, { "tag": "*supplementation" }, { "tag": "Antenatal care", "type": 1 }, { "tag": "Folic acid", "type": 1 }, { "tag": "Knowledge", "type": 1 }, { "tag": "Periconception", "type": 1 }, { "tag": "Pregnancy", "type": 1 }, { "tag": "adult" }, { "tag": "article" }, { "tag": "awareness" }, { "tag": "controlled study" }, { "tag": "cross-sectional study" }, { "tag": "drug therapy" }, { "tag": "employment status" }, { "tag": "family planning" }, { "tag": "female" }, { "tag": "folic acid deficiency" }, { "tag": "health education" }, { "tag": "human" }, { "tag": "incidence" }, { "tag": "low income country" }, { "tag": "neural tube defect" }, { "tag": "nutritional deficiency" }, { "tag": "prevention" }, { "tag": "teaching hospital" } ], "collections": [], "relations": { "dc:replaces": "http://zotero.org/groups/251615/items/5MD9DSCS" }, "dateAdded": "2026-04-07T19:56:54Z", "dateModified": "2026-04-07T20:19:59Z" } }, { "key": "VK3DYW3L", "version": 12181, "library": { "type": "group", "id": 251615, "name": "CentreImage", "links": { "alternate": { "href": "https://www.zotero.org/groups/centreimage", "type": "text/html" } } }, "links": { "self": { "href": "https://api.zotero.org/groups/251615/items/VK3DYW3L", "type": "application/json" }, "alternate": { "href": "https://www.zotero.org/groups/centreimage/items/VK3DYW3L", "type": "text/html" } }, "meta": { "createdByUser": { "id": 14022664, "username": "TeodoraCHUSJ", "name": "", "links": { "alternate": { "href": "https://www.zotero.org/teodorachusj", "type": "text/html" } } }, "creatorSummary": "Feiler et al.", "parsedDate": "2026-03-12", "numChildren": 1 }, "data": { "key": "VK3DYW3L", "version": 12181, "itemType": "journalArticle", "title": "Pregnancy exposure to individual phthalate concentrations and their mixtures in relation to pediatric serum antibody response", "creators": [ { "creatorType": "author", "firstName": "Marina Oktapodas", "lastName": "Feiler" }, { "creatorType": "author", "firstName": "Michele", "lastName": "Salerno" }, { "creatorType": "author", "firstName": "Sally A.", "lastName": "Quataert" }, { "creatorType": "author", "firstName": "Martha M.", "lastName": "Tellez-Rojo" }, { "creatorType": "author", "firstName": "Hector", "lastName": "Lamadrid-Figueroa" }, { "creatorType": "author", "firstName": "Guadalupe", "lastName": "Estrada" }, { "creatorType": "author", "firstName": "Robert O.", "lastName": "Wright" }, { "creatorType": "author", "firstName": "Todd A.", "lastName": "Jusko" }, { "creatorType": "author", "firstName": "Elena", "lastName": "Colicino" } ], "abstractNote": "The objective of this study was to estimate the association between gestational phthalate metabolite concentrations and mixtures and pediatric antibody response at 4-years of age to common childhood vaccines, while also exploring sexually dimorphic effects. This study utilized data from the Programming, Research, Obesity, and Social Stressors (PROGRESS) Study, an ongoing, longitudinal cohort of mother-child pairs residing in Mexico City. Fifteen phthalate metabolites were measured in spot urine samples collected from mothers during their second and third trimesters. Children have been regularly followed, with data collection on lifestyle, clinical, socio-economic, and demographic factors, and archived biologic specimen. IgG-specific antibody serum levels to measles, mumps, rubella, diphtheria, tetanus, and pertussis were quantified from children at the mean 4.7 years of age. Linear regression models, with log2 transformation of both the outcome and exposure variables, estimated the association between individual phthalate metabolites and antibody concentrations. Phthalate mixtures were analyzed using the Quantile G-Computational approach and Bayesian Kernel Machine regression. All analyses were also sex-stratified to investigate sexually dimorphic effects. The present analysis included 362 mother-child pairs. During the second trimester of pregnancy, a doubling increase of mono-2-ethyl-5-carboxypentyl terephthalate (MECPTP) concentrations was associated with a 6.98% decrease (95% CI: - 11.68%, - 2.04%) in diphtheria and a 2.57% decrease (95% CI: - 4.74%, - 0.35%) in mumps antibody levels, respectively. No statistically significant sex-differences were observed. Mixtures analyses did not reach statistical significance but observed similar associations with MECPTP. Concentrations of MECPTP, a replacement phthalate, were negatively associated with anti-diphtheria antibody levels in Hispanic children indicating a potential detrimental effect of newer alternative phthalates on pediatric health.", "publicationTitle": "European Journal of Epidemiology", "publisher": "", "place": "", "date": "2026-03-12", "volume": "", "issue": "", "section": "", "partNumber": "", "partTitle": "", "pages": "", "series": "", "seriesTitle": "", "seriesText": "", "journalAbbreviation": "Eur J Epidemiol", "DOI": "10.1007/s10654-026-01387-1", "citationKey": "", "url": "", "accessDate": "", "PMID": "41817940", "PMCID": "", "ISSN": "1573-7284", "archive": "", "archiveLocation": "", "shortTitle": "", "language": "eng", "libraryCatalog": "PubMed", "callNumber": "", "rights": "", "extra": "", "tags": [ { "tag": "*antibody blood level" }, { "tag": "*antibody response" }, { "tag": "*exposure" }, { "tag": "*phthalic acid" }, { "tag": "*plasticizer" }, { "tag": "*pregnancy" }, { "tag": "*sex difference" }, { "tag": "DTP", "type": 1 }, { "tag": "Gestation", "type": 1 }, { "tag": "Hispanic" }, { "tag": "In-utero", "type": 1 }, { "tag": "MMR", "type": 1 }, { "tag": "Mexico City" }, { "tag": "Plasticizers", "type": 1 }, { "tag": "Sex-differences", "type": 1 }, { "tag": "Vaccine", "type": 1 }, { "tag": "adult" }, { "tag": "article" }, { "tag": "child" }, { "tag": "cohort analysis" }, { "tag": "controlled study" }, { "tag": "diphtheria" }, { "tag": "diphtheria antibody" }, { "tag": "exposure variable" }, { "tag": "female" }, { "tag": "human" }, { "tag": "immunoglobulin G" }, { "tag": "lifestyle" }, { "tag": "major clinical study" }, { "tag": "male" }, { "tag": "measles" }, { "tag": "mumps" }, { "tag": "obesity" }, { "tag": "pertussis" }, { "tag": "preschool child" }, { "tag": "rubella" }, { "tag": "second trimester pregnancy" }, { "tag": "terephthalic acid" }, { "tag": "tetanus" }, { "tag": "third trimester pregnancy" }, { "tag": "urine sampling" } ], "collections": [], "relations": { "dc:replaces": "http://zotero.org/groups/251615/items/LUMB7CBQ" }, "dateAdded": "2026-04-07T19:56:54Z", "dateModified": "2026-04-07T20:19:58Z" } }, { "key": "A5SZB8JH", "version": 12184, "library": { "type": "group", "id": 251615, "name": "CentreImage", "links": { "alternate": { "href": "https://www.zotero.org/groups/centreimage", "type": "text/html" } } }, "links": { "self": { "href": "https://api.zotero.org/groups/251615/items/A5SZB8JH", "type": "application/json" }, "alternate": { "href": "https://www.zotero.org/groups/centreimage/items/A5SZB8JH", "type": "text/html" } }, "meta": { "createdByUser": { "id": 14022664, "username": "TeodoraCHUSJ", "name": "", "links": { "alternate": { "href": "https://www.zotero.org/teodorachusj", "type": "text/html" } } }, "creatorSummary": "Esposito et al.", "parsedDate": "2026-03-18", "numChildren": 1 }, "data": { "key": "A5SZB8JH", "version": 12184, "itemType": "journalArticle", "title": "Lessons from examining the safety of drugs for COVID-19 during pregnancy", "creators": [ { "creatorType": "author", "firstName": "Nunzia", "lastName": "Esposito" }, { "creatorType": "author", "firstName": "Antonio Riccardo", "lastName": "Buonomo" }, { "creatorType": "author", "firstName": "Isabella", "lastName": "Di Filippo" }, { "creatorType": "author", "firstName": "Elisabetta", "lastName": "Forte" }, { "creatorType": "author", "firstName": "Emilia", "lastName": "Trucillo" }, { "creatorType": "author", "firstName": "Ivan", "lastName": "Gentile" }, { "creatorType": "author", "firstName": "Nicola", "lastName": "Schiano Moriello" } ], "abstractNote": "INTRODUCTION: Pregnant women represent a vulnerable population during the COVID-19 pandemic, facing increased risks of severe disease and adverse obstetric outcomes, yet they have been largely excluded from pivotal therapeutic clinical trials, leaving a critical evidence gap for treatment decisions.\nAREAS COVERED: This review examines the available evidence on the safety and efficacy of COVID-19 therapies during pregnancy, including oral antivirals (nirmatrelvir/ritonavir, molnupiravir), intravenous remdesivir, monoclonal antibodies, corticosteroids, and immunomodulators (tocilizumab, baricitinib). A literature search was conducted using MEDLINE/PubMed for English-language articles published from March 2020 to December 2023, including studies of any design reporting maternal and neonatal outcomes.\nEXPERT OPINION: The COVID-19 pandemic exposed a critical gap in clinical research through the systematic exclusion of pregnant women from therapeutic trials. Current evidence, though largely observational, supports vaccination as the primary preventive strategy, nirmatrelvir/ritonavir for outpatients at risk of progression, and remdesivir plus corticosteroids for hospitalized patients requiring oxygen supplementation.", "publicationTitle": "Expert Opinion on Drug Safety", "publisher": "", "place": "", "date": "2026-03-18", "volume": "", "issue": "", "section": "", "partNumber": "", "partTitle": "", "pages": "1-11", "series": "", "seriesTitle": "", "seriesText": "", "journalAbbreviation": "Expert Opin Drug Saf", "DOI": "10.1080/14740338.2026.2637649", "citationKey": "", "url": "", "accessDate": "", "PMID": "41800523", "PMCID": "", "ISSN": "1744-764X", "archive": "", "archiveLocation": "", "shortTitle": "", "language": "eng", "libraryCatalog": "PubMed", "callNumber": "", "rights": "", "extra": "", "tags": [ { "tag": "*antiviral activity" }, { "tag": "*antiviral therapy" }, { "tag": "*antivirus agent" }, { "tag": "*coronavirus disease 2019" }, { "tag": "*monoclonal antibody" }, { "tag": "*pregnancy" }, { "tag": "*remdesivir" }, { "tag": "COVID-19", "type": 1 }, { "tag": "Pregnancy", "type": 1 }, { "tag": "adverse drug reaction" }, { "tag": "antiviral-drugs", "type": 1 }, { "tag": "baricitinib" }, { "tag": "corticosteroid" }, { "tag": "drug therapy" }, { "tag": "human" }, { "tag": "immunomodulating agent" }, { "tag": "immunotherapy" }, { "tag": "molnupiravir" }, { "tag": "monoclonal-antibodies", "type": 1 }, { "tag": "nirmatrelvir plus ritonavir" }, { "tag": "observational study" }, { "tag": "pharmacology" }, { "tag": "pregnancy outcome" }, { "tag": "pregnant woman" }, { "tag": "remdesivir", "type": 1 }, { "tag": "review" }, { "tag": "side effect" }, { "tag": "systematic review" }, { "tag": "therapy" }, { "tag": "tocilizumab" }, { "tag": "vaccination" } ], "collections": [], "relations": { "dc:replaces": "http://zotero.org/groups/251615/items/W48ZEE2L" }, "dateAdded": "2026-04-07T19:56:54Z", "dateModified": "2026-04-07T20:19:57Z" } }, { "key": "32N3HKBS", "version": 12191, "library": { "type": "group", "id": 251615, "name": "CentreImage", "links": { "alternate": { "href": "https://www.zotero.org/groups/centreimage", "type": "text/html" } } }, "links": { "self": { "href": "https://api.zotero.org/groups/251615/items/32N3HKBS", "type": "application/json" }, "alternate": { "href": "https://www.zotero.org/groups/centreimage/items/32N3HKBS", "type": "text/html" } }, "meta": { "createdByUser": { "id": 14022664, "username": "TeodoraCHUSJ", "name": "", "links": { "alternate": { "href": "https://www.zotero.org/teodorachusj", "type": "text/html" } } }, "creatorSummary": "Bebia et al.", "parsedDate": "2026-12", "numChildren": 1 }, "data": { "key": "32N3HKBS", "version": 12191, "itemType": "journalArticle", "title": "Randomized, placebo-controlled phase 3 trial evaluating safety, immunogenicity, and reactogenicity of RSVPreF3-Mat in high-risk pregnant women and their infants", "creators": [ { "creatorType": "author", "firstName": "Zourab", "lastName": "Bebia" }, { "creatorType": "author", "firstName": "Ilse", "lastName": "Dieussaert" }, { "creatorType": "author", "firstName": "Lisa", "lastName": "Jose" }, { "creatorType": "author", "firstName": "Anu", "lastName": "Kantele" }, { "creatorType": "author", "firstName": "Hanna", "lastName": "Välimaa" }, { "creatorType": "author", "firstName": "Guy", "lastName": "Middleton" }, { "creatorType": "author", "firstName": "Hemir David Escobar", "lastName": "Pirela" }, { "creatorType": "author", "firstName": "Osvaldo", "lastName": "Reyes" }, { "creatorType": "author", "firstName": "Marta García", "lastName": "Sánchez" }, { "creatorType": "author", "firstName": "Paulino", "lastName": "Vigil-De Gracia" }, { "creatorType": "author", "firstName": "Nancy", "lastName": "Hua" }, { "creatorType": "author", "firstName": "Martha", "lastName": "Kirabo" }, { "creatorType": "author", "firstName": "Patricia", "lastName": "Lese" }, { "creatorType": "author", "firstName": "Joon Hyung", "lastName": "Kim" } ], "abstractNote": "Respiratory syncytial virus (RSV) causes respiratory illness among infants; maternal vaccination confers passive protection through placental antibody transfer. This phase 3, randomized, placebo-controlled trial evaluated safety, reactogenicity, and immunogenicity of RSV prefusion protein F3 maternal vaccine (RSVPreF3-Mat), administered at 240/7 to 360/7 weeks of gestation to high-risk pregnant women (women with obstetric complications and/or human immunodeficiency virus infection or in pregnant adolescents), and their infants up to 1 year post-birth. Enrollment was stopped and the study unblinded after an increased risk of preterm birth, associated with RSVPreF3 vaccine, was observed in another trial in healthy pregnant women. One hundred and sixty-nine maternal participants received either vaccine or placebo. No serious adverse events in maternal or infant participants were considered vaccine-related. Preterm birth occurred in 18.2% and 19.7% of participants in the vaccine and placebo groups, respectively, with one neonatal death in each group. In the vaccine group, increase in maternal neutralizing antibody titers against RSV subtype A and B was observed at Day 31 post-vaccination and remained high at delivery. Geometric mean ratio of titers at delivery over pre-vaccination for RSV A and B were 8.87- and 8.21-fold, respectively. Similarly, anti-RSVPreF3-Mat immunoglobulin G (IgG) levels showed increase at Day 31 post-vaccination and remained high at delivery (14.12-fold increase over pre-vaccination) with placental transfer ratio of RSVPreF3 IgG-specific antibodies at delivery of 1.33. In this study of high-risk pregnant women, RSVPreF3-Mat demonstrated an acceptable safety profile, induced robust immune responses with successful placental antibody transfer, and showed balanced rates of preterm birth between the groups. Trial registration: EudraCT: 2021-000994-96; NCT: NCT04980391.", "publicationTitle": "Human Vaccines & Immunotherapeutics", "publisher": "", "place": "", "date": "2026-12", "volume": "22", "issue": "1", "section": "", "partNumber": "", "partTitle": "", "pages": "2613565", "series": "", "seriesTitle": "", "seriesText": "", "journalAbbreviation": "Hum Vaccin Immunother", "DOI": "10.1080/21645515.2026.2613565", "citationKey": "", "url": "", "accessDate": "", "PMID": "41766205", "PMCID": "PMC12959198", "ISSN": "2164-554X", "archive": "", "archiveLocation": "", "shortTitle": "", "language": "eng", "libraryCatalog": "PubMed", "callNumber": "", "rights": "", "extra": "", "tags": [ { "tag": "*RSV prefusion protein F3 maternal vaccine/ae [Adverse Drug Reaction]" }, { "tag": "*RSV prefusion protein F3 maternal vaccine/pv [Special Situation for Pharmacovigilance]" }, { "tag": "*biological phenomena and functions concerning organ systems" }, { "tag": "*drug safety" }, { "tag": "*high risk patient" }, { "tag": "*immunogenicity" }, { "tag": "*pregnant woman" }, { "tag": "*reactogenicity" }, { "tag": "*vaccine/ae [Adverse Drug Reaction]" }, { "tag": "*vaccine/pv [Special Situation for Pharmacovigilance]" }, { "tag": "Adolescent", "type": 1 }, { "tag": "Adult", "type": 1 }, { "tag": "Antibodies, Neutralizing", "type": 1 }, { "tag": "Antibodies, Viral", "type": 1 }, { "tag": "Bronchiolitis", "type": 1 }, { "tag": "Female", "type": 1 }, { "tag": "Human immunodeficiency virus infection" }, { "tag": "Humans", "type": 1 }, { "tag": "Immunogenicity, Vaccine", "type": 1 }, { "tag": "Infant", "type": 1 }, { "tag": "Infant, Newborn", "type": 1 }, { "tag": "Pregnancy", "type": 1 }, { "tag": "Pregnancy Complications, Infectious", "type": 1 }, { "tag": "Premature Birth", "type": 1 }, { "tag": "RSV", "type": 1 }, { "tag": "Respiratory Syncytial Virus Infections", "type": 1 }, { "tag": "Respiratory Syncytial Virus Vaccines", "type": 1 }, { "tag": "Respiratory Syncytial Virus, Human", "type": 1 }, { "tag": "Young Adult", "type": 1 }, { "tag": "abdominal pain/si [Side Effect]" }, { "tag": "adolescent" }, { "tag": "adult" }, { "tag": "adverse drug reaction/si [Side Effect]" }, { "tag": "antibody titer" }, { "tag": "article" }, { "tag": "body mass" }, { "tag": "controlled study" }, { "tag": "diarrhea/si [Side Effect]" }, { "tag": "double blind procedure" }, { "tag": "enzyme linked immunosorbent assay" }, { "tag": "erythema/si [Side Effect]" }, { "tag": "false labor/si [Side Effect]" }, { "tag": "fatigue/si [Side Effect]" }, { "tag": "female" }, { "tag": "fever/si [Side Effect]" }, { "tag": "gestational diabetes/co [Complication]" }, { "tag": "headache/si [Side Effect]" }, { "tag": "heart disease/si [Side Effect]" }, { "tag": "human" }, { "tag": "humoral immunity", "type": 1 }, { "tag": "immune response" }, { "tag": "immunoglobulin G/ec [Endogenous Compound]" }, { "tag": "infant" }, { "tag": "injection site contusion/si [Side Effect]" }, { "tag": "injection site reaction/si [Side Effect]" }, { "tag": "intrauterine growth retardation/co [Complication]" }, { "tag": "major clinical study" }, { "tag": "male" }, { "tag": "maternal hypertension/co [Complication]" }, { "tag": "maternal immunization", "type": 1 }, { "tag": "nausea/si [Side Effect]" }, { "tag": "neonatal care", "type": 1 }, { "tag": "neutralizing antibody" }, { "tag": "newborn death" }, { "tag": "pain/si [Side Effect]" }, { "tag": "passive immunization", "type": 1 }, { "tag": "phase 3 clinical trial" }, { "tag": "placental transfer", "type": 1 }, { "tag": "postpartum hemorrhage/si [Side Effect]" }, { "tag": "preeclampsia/co [Complication]" }, { "tag": "preeclampsia/si [Side Effect]" }, { "tag": "pregnancy", "type": 1 }, { "tag": "premature labor/si [Side Effect]" }, { "tag": "prematurity" }, { "tag": "preterm birth", "type": 1 }, { "tag": "reduced fetal movement/si [Side Effect]" }, { "tag": "respiratory tract disease" }, { "tag": "respiratory tract infection" }, { "tag": "swelling/si [Side Effect]" }, { "tag": "unclassified drug" }, { "tag": "vaccination" }, { "tag": "vaccines", "type": 1 }, { "tag": "vomiting/si [Side Effect]" } ], "collections": [], "relations": { "dc:replaces": "http://zotero.org/groups/251615/items/SR8HPJUE" }, "dateAdded": "2026-04-07T19:56:54Z", "dateModified": "2026-04-07T20:19:56Z" } }, { "key": "HFN3XIKD", "version": 12190, "library": { "type": "group", "id": 251615, "name": "CentreImage", "links": { "alternate": { "href": "https://www.zotero.org/groups/centreimage", "type": "text/html" } } }, "links": { "self": { "href": "https://api.zotero.org/groups/251615/items/HFN3XIKD", "type": "application/json" }, "alternate": { "href": "https://www.zotero.org/groups/centreimage/items/HFN3XIKD", "type": "text/html" } }, "meta": { "createdByUser": { "id": 14022664, "username": "TeodoraCHUSJ", "name": "", "links": { "alternate": { "href": "https://www.zotero.org/teodorachusj", "type": "text/html" } } }, "creatorSummary": "Ayas Özkan et al.", "parsedDate": "2026-03-03", "numChildren": 1 }, "data": { "key": "HFN3XIKD", "version": 12190, "itemType": "journalArticle", "title": "Diagnostic and prognostic role of maternal serum prokineticin-1 in preeclampsia and adverse pregnancy outcomes", "creators": [ { "creatorType": "author", "firstName": "Merve", "lastName": "Ayas Özkan" }, { "creatorType": "author", "firstName": "Aziz", "lastName": "Kından" }, { "creatorType": "author", "firstName": "İslam", "lastName": "Aslanlı" }, { "creatorType": "author", "firstName": "Kadriye", "lastName": "Yakut Yücel" } ], "abstractNote": "OBJECTIVE: Prokineticin-1 (PROK-1), known as endocrine gland-derived vascular endothelial growth factor, is an angiogenic peptide mostly produced in endocrine and placental organs. It is important for placental vascular remodeling and trophoblast control. This study sought to investigate the potential of maternal serum PROK-1 levels as a diagnostic or prognostic marker in preeclampsia (PE).\nMATERIAL AND METHODS: This prospective case-control study included women diagnosed with PE and normotensive pregnant controls. Serum samples were collected at hospital admission, and PROK-1 concentrations were quantified using a commercial ELISA kit. Clinical characteristics and perinatal outcomes were compared between groups. Receiver operating characteristic analyses were used to assess the diagnostic and prognostic performance of PROK-1 for PE, disease severity, and composite adverse perinatal outcomes (CAPO).\nRESULTS: There were 45 women in the PE group and an equal number of controls. PROK-1 levels were significantly higher in PE than in controls [8.37 (10.51) vs. 4.89 (3.26) ng/mL, p<0.001). PROK-1 predicted PE with an area under the curve (AUC) of 0.721 (cut-off >5.40 ng/mL; sensitivity 75.6%, specificity 60.0%; positive predictive value 65.5%, negative predictive value 71.4%). Furthermore, severe PE cases had significantly higher PROK-1 levels than mild PE cases. PROK-1 predicted severe PE with an AUC of 0.716 (cut-off >9.80 ng/mL) and CAPO with an AUC of 0.673 (cut-off >6.53 ng/mL).\nCONCLUSION: Maternal serum PROK-1 was elevated in PE and correlated with disease severity and adverse perinatal outcomes. Although inadequate as a stand-alone marker, PROK-1 may complement existing angiogenic biomarkers in multimarker prediction models.", "publicationTitle": "Journal of the Turkish German Gynecological Association", "publisher": "", "place": "", "date": "2026-03-03", "volume": "27", "issue": "1", "section": "", "partNumber": "", "partTitle": "", "pages": "43-50", "series": "", "seriesTitle": "", "seriesText": "", "journalAbbreviation": "J Turk Ger Gynecol Assoc", "DOI": "10.4274/jtgga.galenos.2026.2025-10-12", "citationKey": "", "url": "", "accessDate": "", "PMID": "41773024", "PMCID": "PMC12954624", "ISSN": "1309-0399", "archive": "", "archiveLocation": "", "shortTitle": "", "language": "eng", "libraryCatalog": "PubMed", "callNumber": "", "rights": "", "extra": "", "tags": [ { "tag": "*endocrine gland derived vascular endothelial growth factor" }, { "tag": "*preeclampsia" }, { "tag": "*pregnancy" }, { "tag": "*pregnancy outcome" }, { "tag": "ELISA kit" }, { "tag": "G Power 3.0.10 software" }, { "tag": "Preeclampsia", "type": 1 }, { "tag": "SPSS version 30.0" }, { "tag": "Youden index" }, { "tag": "adult" }, { "tag": "angiogenesis" }, { "tag": "area under the curve" }, { "tag": "article" }, { "tag": "biochemical analysis" }, { "tag": "biological marker" }, { "tag": "biomarkers", "type": 1 }, { "tag": "birth weight" }, { "tag": "body mass" }, { "tag": "case control study" }, { "tag": "cesarean section" }, { "tag": "clinical article" }, { "tag": "cohort analysis" }, { "tag": "confidence interval" }, { "tag": "controlled study" }, { "tag": "data analysis software" }, { "tag": "demographics" }, { "tag": "diagnostic test accuracy study" }, { "tag": "diastolic blood pressure" }, { "tag": "disease severity" }, { "tag": "endocrine gland" }, { "tag": "female" }, { "tag": "fetus growth" }, { "tag": "gestational age" }, { "tag": "gestational diabetes" }, { "tag": "homeostasis" }, { "tag": "hospital admission" }, { "tag": "human" }, { "tag": "hypertension" }, { "tag": "intrauterine growth retardation" }, { "tag": "major clinical study" }, { "tag": "maternal hypertension" }, { "tag": "maternal serum" }, { "tag": "morbidity" }, { "tag": "mortality" }, { "tag": "neonatal intensive care unit" }, { "tag": "observational study" }, { "tag": "outcome assessment" }, { "tag": "predictive value" }, { "tag": "pregnancy outcome", "type": 1 }, { "tag": "prokineticin-1", "type": 1 }, { "tag": "prospective study" }, { "tag": "proteinuria" }, { "tag": "questionnaire" }, { "tag": "rank sum test" }, { "tag": "receiver operating characteristic" }, { "tag": "risk factor" }, { "tag": "sample size" }, { "tag": "systolic blood pressure" }, { "tag": "trophoblast" }, { "tag": "vaginal delivery" }, { "tag": "vascular remodeling" }, { "tag": "vasculotropin" } ], "collections": [], "relations": { "dc:replaces": "http://zotero.org/groups/251615/items/3K4JAH48" }, "dateAdded": "2026-04-07T19:56:54Z", "dateModified": "2026-04-07T20:19:54Z" } }, { "key": "PXLMKVWV", "version": 12186, "library": { "type": "group", "id": 251615, "name": "CentreImage", "links": { "alternate": { "href": "https://www.zotero.org/groups/centreimage", "type": "text/html" } } }, "links": { "self": { "href": "https://api.zotero.org/groups/251615/items/PXLMKVWV", "type": "application/json" }, "alternate": { "href": "https://www.zotero.org/groups/centreimage/items/PXLMKVWV", "type": "text/html" } }, "meta": { "createdByUser": { "id": 14022664, "username": "TeodoraCHUSJ", "name": "", "links": { "alternate": { "href": "https://www.zotero.org/teodorachusj", "type": "text/html" } } }, "creatorSummary": "Adomi et al.", "parsedDate": "2026-03-07", "numChildren": 1 }, "data": { "key": "PXLMKVWV", "version": 12186, "itemType": "journalArticle", "title": "Medication use during pregnancy in Japan from 2005 to 2019: Trends and safety considerations", "creators": [ { "creatorType": "author", "firstName": "Motohiko", "lastName": "Adomi" }, { "creatorType": "author", "firstName": "Takamasa", "lastName": "Sakai" }, { "creatorType": "author", "firstName": "Tomofumi", "lastName": "Ishikawa" }, { "creatorType": "author", "firstName": "Taku", "lastName": "Obara" }, { "creatorType": "author", "firstName": "Krista F.", "lastName": "Huybrechts" } ], "abstractNote": "OBJECTIVE: Recent data on patterns and trends of medication use during pregnancy are limited in Japan. This study aimed to evaluate annual trends of medication use during pregnancy in Japan and identify frequently dispensed medications with limited safety evidence.\nMETHODS: A descriptive study was conducted using a pregnancy cohort nested within the JMDC claims database (2005-2019). Dispensing of medications before pregnancy and during each pregnancy trimester were evaluated. Annual trends were examined at the class and subclass medication level. Availability of evidence on teratogenic risk was assessed for the top 30 most commonly dispensed medications during the first trimester using the TERIS database.\nRESULTS: A total of 110 969 pregnancies (94 749 unique individuals) were included in the study. Acetaminophen was the most commonly dispensed medication across all windows. Other frequently dispensed medications included other analgesics, antiasthmatics, antibiotics, antiemetics, antiulcer medications, immunosuppressants, and thyroid medications. Annual trends revealed increased dispensing of analgesics (primarily acetaminophen), antiasthmatics (inhaled beta-2 agonists, inhaled corticosteroids, leukotriene receptor antagonists), antiemetics (metoclopramide), and thyroid medications (thyroid hormone). Over 60% of the 30 most commonly dispensed medications during the first trimester lacked sufficient teratogenic safety evidence, particularly for antiasthmatics, antibiotics, and antivirals.\nCONCLUSION: A significant proportion of medications commonly dispensed during pregnancy in Japan have inadequate teratogenic safety evidence. Several medication classes showed increasing utilization trends over the study period, emphasizing the urgent need for targeted safety evaluations in the Japanese population.", "publicationTitle": "International Journal of Gynaecology and Obstetrics: The Official Organ of the International Federation of Gynaecology and Obstetrics", "publisher": "", "place": "", "date": "2026-03-07", "volume": "", "issue": "", "section": "", "partNumber": "", "partTitle": "", "pages": "", "series": "", "seriesTitle": "", "seriesText": "", "journalAbbreviation": "Int J Gynaecol Obstet", "DOI": "10.1002/ijgo.70860", "citationKey": "", "url": "", "accessDate": "", "PMID": "41795143", "PMCID": "", "ISSN": "1879-3479", "archive": "", "archiveLocation": "", "shortTitle": "Medication use during pregnancy in Japan from 2005 to 2019", "language": "eng", "libraryCatalog": "PubMed", "callNumber": "", "rights": "", "extra": "", "tags": [ { "tag": "*Japan" }, { "tag": "*drug use" }, { "tag": "*drug utilization" }, { "tag": "*pregnancy" }, { "tag": "*teratogenicity" }, { "tag": "International Federation of Gynecology and Obstetrics" }, { "tag": "Japan", "type": 1 }, { "tag": "Japanese (people)" }, { "tag": "adolescent" }, { "tag": "adult" }, { "tag": "analgesic agent" }, { "tag": "antiasthmatic agent" }, { "tag": "antibiotic agent" }, { "tag": "antiemetic agent" }, { "tag": "antiulcer agent" }, { "tag": "antiviral activity" }, { "tag": "antivirus agent" }, { "tag": "article" }, { "tag": "child" }, { "tag": "cohort analysis" }, { "tag": "controlled study" }, { "tag": "corticosteroid" }, { "tag": "drug concentration" }, { "tag": "drug therapy" }, { "tag": "drug utilization", "type": 1 }, { "tag": "female" }, { "tag": "first trimester pregnancy" }, { "tag": "human" }, { "tag": "immunosuppressive agent" }, { "tag": "immunosuppressive treatment" }, { "tag": "inhalation" }, { "tag": "inhalational drug administration" }, { "tag": "leukotriene receptor blocking agent" }, { "tag": "male" }, { "tag": "metoclopramide" }, { "tag": "paracetamol" }, { "tag": "pharmacoeconomics" }, { "tag": "pregnancy", "type": 1 }, { "tag": "safety assessment" }, { "tag": "special situation for pharmacovigilance" }, { "tag": "teratogenicity", "type": 1 }, { "tag": "therapy" }, { "tag": "thyroid hormone" }, { "tag": "young adult" } ], "collections": [], "relations": { "dc:replaces": "http://zotero.org/groups/251615/items/ZI2DSSJC" }, "dateAdded": "2026-04-07T19:56:54Z", "dateModified": "2026-04-07T20:19:53Z" } }, { "key": "TXLCRKII", "version": 12174, "library": { "type": "group", "id": 251615, "name": "CentreImage", "links": { "alternate": { "href": "https://www.zotero.org/groups/centreimage", "type": "text/html" } } }, "links": { "self": { "href": "https://api.zotero.org/groups/251615/items/TXLCRKII", "type": "application/json" }, "alternate": { "href": "https://www.zotero.org/groups/centreimage/items/TXLCRKII", "type": "text/html" } }, "meta": { "createdByUser": { "id": 14022664, "username": "TeodoraCHUSJ", "name": "", "links": { "alternate": { "href": "https://www.zotero.org/teodorachusj", "type": "text/html" } } }, "creatorSummary": "Badell et al.", "parsedDate": "2022", "numChildren": 0 }, "data": { "key": "TXLCRKII", "version": 12174, "itemType": "journalArticle", "title": "Covid-19 vaccination in pregnancy", "creators": [ { "creatorType": "author", "firstName": "M. L.", "lastName": "Badell" }, { "creatorType": "author", "firstName": "C. M.", "lastName": "Dude" }, { "creatorType": "author", "firstName": "S. A.", "lastName": "Rasmussen" }, { "creatorType": "author", "firstName": "D. J.", "lastName": "Jamieson" } ], "abstractNote": "Pregnancy is an independent risk factor for severe covid-19. Vaccination is the best way to reduce the risk for SARS-CoV-2 infection and limit its morbidity and mortality. The current recommendations from the World Health Organization, Centers for Disease Control and Prevention, and professional organizations are for pregnant, postpartum, and lactating women to receive covid-19 vaccination. Pregnancy specific considerations involve potential effects of vaccination on fetal development, placental transfer of antibodies, and safety of maternal vaccination. Although pregnancy was an exclusion criterion in initial clinical trials of covid-19 vaccines, observational data have been rapidly accumulating and thus far confirm that the benefits of vaccination outweigh the potential risks. This review examines the evidence supporting the effectiveness, immunogenicity, placental transfer, side effects, and perinatal outcomes of maternal covid-19 vaccination. Additionally, it describes factors associated with vaccine hesitancy in pregnancy. Overall, studies monitoring people who have received covid-19 vaccines during pregnancy have not identified any pregnancy specific safety concerns. Additional information on non-mRNA vaccines, vaccination early in pregnancy, and longer term outcomes in infants are needed. To collect this information, vaccination during pregnancy must be prioritized in vaccine research.Copyright © Published by the BMJ Publishing Group Limited.", "publicationTitle": "The BMJ", "publisher": "", "place": "", "date": "2022", "volume": "", "issue": "", "section": "", "partNumber": "", "partTitle": "", "pages": "e069741", "series": "", "seriesTitle": "", "seriesText": "", "journalAbbreviation": "", "DOI": "10.1136/bmj-2021-069741", "citationKey": "", "url": "http://www.bmj.com/ https://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=emed23&NEWS=N&AN=2019847631", "accessDate": "", "PMID": "", "PMCID": "", "ISSN": "0959-8146 1756-1833", "archive": "Embase", "archiveLocation": "2019847631", "shortTitle": "", "language": "English", "libraryCatalog": "", "callNumber": "", "rights": "", "extra": "", "tags": [ { "tag": "*coronavirus disease 2019" }, { "tag": "*pregnancy" }, { "tag": "*vaccination" }, { "tag": "SARS-CoV-2 vaccine" }, { "tag": "World Health Organization" }, { "tag": "adult" }, { "tag": "clinical trial" }, { "tag": "disease control" }, { "tag": "drug safety" }, { "tag": "drug therapy" }, { "tag": "female" }, { "tag": "fetus development" }, { "tag": "first trimester pregnancy" }, { "tag": "human" }, { "tag": "immunogenicity" }, { "tag": "infant" }, { "tag": "medical society" }, { "tag": "morbidity" }, { "tag": "mortality" }, { "tag": "outcome assessment" }, { "tag": "placental transfer" }, { "tag": "review" }, { "tag": "risk factor" }, { "tag": "vaccine hesitancy" } ], "collections": [ "34HIUU9M" ], "relations": { "dc:replaces": "http://zotero.org/groups/251615/items/4X8CHIH4" }, "dateAdded": "2026-03-03T21:19:46Z", "dateModified": "2026-04-07T20:19:52Z" } }, { "key": "QZGUAYL9", "version": 12173, "library": { "type": "group", "id": 251615, "name": "CentreImage", "links": { "alternate": { "href": "https://www.zotero.org/groups/centreimage", "type": "text/html" } } }, "links": { "self": { "href": "https://api.zotero.org/groups/251615/items/QZGUAYL9", "type": "application/json" }, "alternate": { "href": "https://www.zotero.org/groups/centreimage/items/QZGUAYL9", "type": "text/html" } }, "meta": { "createdByUser": { "id": 14022664, "username": "TeodoraCHUSJ", "name": "", "links": { "alternate": { "href": "https://www.zotero.org/teodorachusj", "type": "text/html" } } }, "creatorSummary": "Dhiman et al.", "parsedDate": "2026", "numChildren": 0 }, "data": { "key": "QZGUAYL9", "version": 12173, "itemType": "journalArticle", "title": "Pregnancy After Renal Transplantation: Diagnostic Challenge of Distinguishing Severe Preeclampsia from Acute Graft Rejection-A Case Report and Review", "creators": [ { "creatorType": "author", "firstName": "S.", "lastName": "Dhiman" }, { "creatorType": "author", "firstName": "K. A.", "lastName": "Sharma" }, { "creatorType": "author", "firstName": "S.", "lastName": "Bharti" }, { "creatorType": "author", "firstName": "J.", "lastName": "Bharti" }, { "creatorType": "author", "firstName": "R. K.", "lastName": "Yadav" }, { "creatorType": "author", "firstName": "N.", "lastName": "Malhotra" } ], "abstractNote": "Background: Pregnancy after renal transplantation is increasingly encountered due to improved graft survival and safer immunosuppressive regimens. These pregnancies remain high-risk, with substantial maternal and fetal morbidity. Distinguishing severe preeclampsia from acute graft rejection poses a major diagnostic challenge, as both conditions share overlapping clinical features. This report highlights such a dilemma in the management of a renal transplant recipient with deteriorating renal parameters and hypertension in the late second trimester. Case: A 29-year-old multigravida, a live donor renal transplant recipient with history of earlyonset severe preeclampsia and early neonatal loss conceived spontaneously. In current pregnancy, initial antenatal evaluation revealed stable graft function and normal aneuploidy screening. At 29 weeks, she developed severe hypertension, worsening proteinuria, rising creatinine, fetal growth restriction, and a culture-positive urinary tract infection. Despite intensified antihypertensive therapy, renal parameters continued to decline. The sFlt-1/PLGF ratio was borderline (84.5), leaving diagnostic uncertainty regarding preeclampsia versus acute graft rejection. An ultrasound-guided renal graft biopsy was performed, demonstrating interstitial fibrosis and tubular atrophy without rejection. Management proceeded along the preeclampsia protocol with strict surveillance. Progression to reverse end-diastolic flow and recurrent fetal decelerations necessitated emergency caesarean delivery at 31 weeks. Postpartum, patient achieved stable renal function and blood pressure, while preterm neonate required extended NICU care, however both were discharged in stable condition. Conclusion(s): Pregnancy in renal transplant recipients requires meticulous multidisciplinary care. In cases where preeclampsia and graft dysfunction coexist, angiogenic biomarkers and selective renal biopsy can provide crucial diagnostic clarity. With individualized management, favourable maternal and neonatal outcomes are achievable even in complex scenarios.Copyright © The Author(s), under exclusive licence to the Federation of Obstetric & Gynecological Societies of India 2026.", "publicationTitle": "Journal of Obstetrics and Gynecology of India", "publisher": "", "place": "", "date": "2026", "volume": "", "issue": "", "section": "", "partNumber": "", "partTitle": "", "pages": "", "series": "", "seriesTitle": "", "seriesText": "", "journalAbbreviation": "", "DOI": "10.1007/s13224-026-02358-y", "citationKey": "", "url": "https://www.springer.com/journal/13224 https://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=emedx&NEWS=N&AN=2043379506", "accessDate": "", "PMID": "", "PMCID": "", "ISSN": "0971-9202 0975-6434", "archive": "Embase Daily Updates", "archiveLocation": "2043379506", "shortTitle": "", "language": "English", "libraryCatalog": "", "callNumber": "", "rights": "", "extra": "", "tags": [ { "tag": "*acute graft rejection" }, { "tag": "*graft rejection" }, { "tag": "*high risk pregnancy" }, { "tag": "*kidney transplantation" }, { "tag": "*preeclampsia" }, { "tag": "*pregnancy" }, { "tag": "adult" }, { "tag": "aneuploidy" }, { "tag": "angiogenesis" }, { "tag": "antihypertensive therapy" }, { "tag": "article" }, { "tag": "biological marker" }, { "tag": "blood pressure" }, { "tag": "case report" }, { "tag": "clinical article" }, { "tag": "clinical feature" }, { "tag": "complication" }, { "tag": "creatinine" }, { "tag": "deceleration" }, { "tag": "diagnosis" }, { "tag": "drug administration" }, { "tag": "drug combination" }, { "tag": "female" }, { "tag": "graft recipient" }, { "tag": "graft survival" }, { "tag": "human" }, { "tag": "human tissue" }, { "tag": "hypertension" }, { "tag": "immunosuppressive treatment" }, { "tag": "intrauterine growth retardation" }, { "tag": "intravenous drug administration" }, { "tag": "kidney biopsy" }, { "tag": "kidney function" }, { "tag": "kidney graft" }, { "tag": "living donor" }, { "tag": "multigravida" }, { "tag": "neonatal intensive care unit" }, { "tag": "prematurity" }, { "tag": "proteinuria" }, { "tag": "protocol" }, { "tag": "second trimester pregnancy" }, { "tag": "therapy" }, { "tag": "urinary tract infection" } ], "collections": [ "3KB9AC33" ], "relations": { "dc:replaces": "http://zotero.org/groups/251615/items/K39TYN79" }, "dateAdded": "2026-03-03T21:19:43Z", "dateModified": "2026-04-07T20:19:51Z" } }, { "key": "XEJFUIVN", "version": 12171, "library": { "type": "group", "id": 251615, "name": "CentreImage", "links": { "alternate": { "href": "https://www.zotero.org/groups/centreimage", "type": "text/html" } } }, "links": { "self": { "href": "https://api.zotero.org/groups/251615/items/XEJFUIVN", "type": "application/json" }, "alternate": { "href": "https://www.zotero.org/groups/centreimage/items/XEJFUIVN", "type": "text/html" } }, "meta": { "createdByUser": { "id": 14022664, "username": "TeodoraCHUSJ", "name": "", "links": { "alternate": { "href": "https://www.zotero.org/teodorachusj", "type": "text/html" } } }, "creatorSummary": "Ekinci et al.", "parsedDate": "2025", "numChildren": 0 }, "data": { "key": "XEJFUIVN", "version": 12171, "itemType": "journalArticle", "title": "Do Obstetricians' Knowledge and Approaches to HIV and Pregnancy Reflect the State-of-the-Art Literature in the Era of Contemporary ARTs, U=U, and PrEP?", "creators": [ { "creatorType": "author", "firstName": "S. C.", "lastName": "Ekinci" }, { "creatorType": "author", "firstName": "E.", "lastName": "Yenilmez" }, { "creatorType": "author", "firstName": "T.", "lastName": "Yetginakin" }, { "creatorType": "author", "firstName": "A.", "lastName": "Senyuva" }, { "creatorType": "author", "firstName": "A.", "lastName": "Kucukbirer" }, { "creatorType": "author", "firstName": "B.", "lastName": "Denizoglu" }, { "creatorType": "author", "firstName": "H.", "lastName": "Keles" } ], "abstractNote": "Introduction: Obstetricians are very important intermediaries for reaching and engaging with women living with Human Immunodeficiency Virus (HIV) or women at risk for acquiring HIV. Thus, they should acquire up-to-date HIV knowledge for them to make clinical decisions in prepregnancy counseling and follow-up of HIV-positive pregnant women. Material(s) and Method(s): This study assessed obstetricians' knowledge about HIV and pregnancy and their behaviors regarding the follow-up of HIV-positive pregnant women using a 54-item face-to-face and online questionnaire administered to physicians working in Turkiye between February and May 2023. This cross-sectional study questionnaire consists of four sections including following up of HIV+ pregnancies, knowledge of HIV, undetectable=untransmittable (U=U) pre-exposure prophylaxis (PrEP), and patient management or treatment approaches. Result(s): A total of 133 obstetricians and gynecologists, comprising 15 (11.3%) academic members, 43 (32.3%) specialists, and 75 (56.4%) residents, participated in this study. A significant proportion of respondents felt that they knew nothing (2.2%) or little (34.6%) about HIV/Acquired Immunodeficiency Syndrome. A substantial proportion of respondents with <5 years of experience (40.5%, p=0.001) stated they had never attended a scientific meeting on HIV and had never read a guideline or article, whereas 34.6% had never followed up an HIV-positive pregnancy, and 43.6% reported having followed up only one to five HIV-positive pregnancies. Of the participants, 49.6% believed that HIV is an infection that will continue to progress and lead to death despite treatment, 74.4% reported they had never heard of the term U=U, and only 18.8% stated they had some knowledge on PrEP. Knowledge regarding the use of semen preparation techniques and indications for cesarean section and intravenous zidovudine in pregnant women with HIV was reportedly lacking. Conclusion(s): The knowledge level on HIV, the disease course, the efficacy of antiretroviral drugs, and the use of these drugs in pregnancy among obstetricians participating in our study is insufficient. Considering that the incidence and prevalence of HIV will continue to increase significantly in the coming years and that a significant proportion of this increase will be young women of childbearing age, obstetricians and gynecologists must keep themselves up-to-date on HIV and pregnancy.Copyright © 2025 The Author. Published by Galenos Publishing House on behalf of Infectious Diseases and Clinical Microbiology Specialty Society of Turkey.", "publicationTitle": "Mediterranean Journal of Infection, Microbes and Antimicrobials", "publisher": "", "place": "", "date": "2025", "volume": "14", "issue": "1", "section": "", "partNumber": "", "partTitle": "", "pages": "25386.9", "series": "Gunumuz ART, U=U ve PrEP Doneminde Obstetrisyenlerin HIV ve Gebelige Yonelik Bilgi ve Yaklasimlari Guncel Literaturu Yansitiyor mu?", "seriesTitle": "", "seriesText": "", "journalAbbreviation": "", "DOI": "10.4274/mjima.galenos.2025.25386.9", "citationKey": "", "url": "https://www.mjima.org/ https://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=emexb&NEWS=N&AN=2037685803", "accessDate": "", "PMID": "", "PMCID": "", "ISSN": "2147-673X (electronic) 2147-673X", "archive": "Embase Weekly Updates", "archiveLocation": "2037685803", "shortTitle": "", "language": "English", "libraryCatalog": "", "callNumber": "", "rights": "", "extra": "", "tags": [ { "tag": "*Human immunodeficiency virus" }, { "tag": "*Human immunodeficiency virus infection/di [Diagnosis]" }, { "tag": "*Human immunodeficiency virus infection/dt [Drug Therapy]" }, { "tag": "*Human immunodeficiency virus infection/pc [Prevention]" }, { "tag": "*antiretroviral therapy" }, { "tag": "*antiretrovirus agent/dt [Drug Therapy]" }, { "tag": "*knowledge" }, { "tag": "*obstetrician" }, { "tag": "*obstetrician knowledge" }, { "tag": "*physician attitude" }, { "tag": "*pre-exposure prophylaxis" }, { "tag": "*pregnancy" }, { "tag": "*pregnant woman" }, { "tag": "*undetectable untransmittable" }, { "tag": "HIV test" }, { "tag": "Human immunodeficiency virus infected patient" }, { "tag": "Turkey (republic)" }, { "tag": "acquired immune deficiency syndrome/di [Diagnosis]" }, { "tag": "acquired immune deficiency syndrome/dt [Drug Therapy]" }, { "tag": "acquired immune deficiency syndrome/pc [Prevention]" }, { "tag": "adult" }, { "tag": "article" }, { "tag": "cesarean section" }, { "tag": "clinical decision making" }, { "tag": "counseling" }, { "tag": "cross-sectional study" }, { "tag": "death" }, { "tag": "drug therapy" }, { "tag": "face-to-face interview" }, { "tag": "female" }, { "tag": "follow up" }, { "tag": "gynecologist" }, { "tag": "human" }, { "tag": "incidence" }, { "tag": "male" }, { "tag": "medical specialist" }, { "tag": "nonhuman" }, { "tag": "online questionnaire" }, { "tag": "patient care" }, { "tag": "practice guideline" }, { "tag": "pregnant woman" }, { "tag": "prevalence" }, { "tag": "prevention" }, { "tag": "questionnaire" }, { "tag": "resident" }, { "tag": "secondary care center" }, { "tag": "sperm preparation" }, { "tag": "tertiary care center" }, { "tag": "treatment indication" }, { "tag": "virus detection" }, { "tag": "virus load" }, { "tag": "virus transmission" }, { "tag": "work experience" }, { "tag": "zidovudine" }, { "tag": "zidovudine/dt [Drug Therapy]" }, { "tag": "zidovudine/iv [Intravenous Drug Administration]" } ], "collections": [ "3KB9AC33" ], "relations": { "dc:replaces": "http://zotero.org/groups/251615/items/5U4FR3SG" }, "dateAdded": "2026-03-03T21:19:42Z", "dateModified": "2026-04-07T20:19:50Z" } }, { "key": "67LSJPPL", "version": 12172, "library": { "type": "group", "id": 251615, "name": "CentreImage", "links": { "alternate": { "href": "https://www.zotero.org/groups/centreimage", "type": "text/html" } } }, "links": { "self": { "href": "https://api.zotero.org/groups/251615/items/67LSJPPL", "type": "application/json" }, "alternate": { "href": "https://www.zotero.org/groups/centreimage/items/67LSJPPL", "type": "text/html" } }, "meta": { "createdByUser": { "id": 14022664, "username": "TeodoraCHUSJ", "name": "", "links": { "alternate": { "href": "https://www.zotero.org/teodorachusj", "type": "text/html" } } }, "creatorSummary": "Dwyer et al.", "parsedDate": "2022", "numChildren": 0 }, "data": { "key": "67LSJPPL", "version": 12172, "itemType": "journalArticle", "title": "Who should consume high-dose folic acid supplements before and during early pregnancy for the prevention of neural tube defects?", "creators": [ { "creatorType": "author", "firstName": "E. R.", "lastName": "Dwyer" }, { "creatorType": "author", "firstName": "K. B.", "lastName": "Filion" }, { "creatorType": "author", "firstName": "A. J.", "lastName": "MacFarlane" }, { "creatorType": "author", "firstName": "R. W.", "lastName": "Platt" }, { "creatorType": "author", "firstName": "A.", "lastName": "Mehrabadi" } ], "abstractNote": "", "publicationTitle": "The BMJ", "publisher": "", "place": "", "date": "2022", "volume": "", "issue": "", "section": "", "partNumber": "", "partTitle": "", "pages": "e067728", "series": "", "seriesTitle": "", "seriesText": "", "journalAbbreviation": "", "DOI": "10.1136/bmj-2021-067728", "citationKey": "", "url": "http://www.bmj.com/ https://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=emed23&NEWS=N&AN=638289569", "accessDate": "", "PMID": "", "PMCID": "", "ISSN": "0959-8146 1756-1833", "archive": "Embase", "archiveLocation": "638289569", "shortTitle": "", "language": "English", "libraryCatalog": "", "callNumber": "", "rights": "", "extra": "", "tags": [ { "tag": "*first trimester pregnancy" }, { "tag": "*folic acid" }, { "tag": "*neural tube defect" }, { "tag": "article" }, { "tag": "drug megadose" }, { "tag": "human" }, { "tag": "prevention" } ], "collections": [ "3KB9AC33" ], "relations": { "dc:replaces": "http://zotero.org/groups/251615/items/SM72N5R3" }, "dateAdded": "2026-03-03T21:19:42Z", "dateModified": "2026-04-07T20:19:49Z" } }, { "key": "PAXNQUVI", "version": 12170, "library": { "type": "group", "id": 251615, "name": "CentreImage", "links": { "alternate": { "href": "https://www.zotero.org/groups/centreimage", "type": "text/html" } } }, "links": { "self": { "href": "https://api.zotero.org/groups/251615/items/PAXNQUVI", "type": "application/json" }, "alternate": { "href": "https://www.zotero.org/groups/centreimage/items/PAXNQUVI", "type": "text/html" } }, "meta": { "createdByUser": { "id": 14022664, "username": "TeodoraCHUSJ", "name": "", "links": { "alternate": { "href": "https://www.zotero.org/teodorachusj", "type": "text/html" } } }, "creatorSummary": "Khairoh et al.", "parsedDate": "2026", "numChildren": 0 }, "data": { "key": "PAXNQUVI", "version": 12170, "itemType": "journalArticle", "title": "Syzygium cumini Fraction Modulates IFN-gamma, Ki67, and IL-10 in Pregnant Murine Model of Malaria", "creators": [ { "creatorType": "author", "firstName": "M.", "lastName": "Khairoh" }, { "creatorType": "author", "firstName": "A.", "lastName": "Prayitno" }, { "creatorType": "author", "firstName": "L.", "lastName": "Maslachah" }, { "creatorType": "author", "name": "Soetrisno" }, { "creatorType": "author", "firstName": "P.", "lastName": "Dirgahayu" } ], "abstractNote": "Malaria in pregnancy significantly increases maternal and fetal morbidity and mortality, underscoring the need for effective interventions. This study aimed to evaluate the immunomodulatory effects of Syzygium cumini fruit chloroform-methanol fraction, specifically on interferon gamma (IFN-gamma), interleukin-10 (IL-10), and antigen Kiel 67 (Ki-67) expressions in a murine model of malaria in pregnancy. Fifty-four (54) healthy pregnant Balb/c mice were divided into six groups of nine mice each: Normal control (NC) - pregnant non-infected mice, Negative control (NegC) - Pregnant infected mice only, Positive control (PosC) - infected mice treated with standard antimalarial (Dihydroartemisinin 40 mg/Piperaquine phosphate 320 mg), and three treatment groups T1, T2, and T3 which consist of infected mice treated with S. cumini fraction at 600, 800, and 1200 mg/kg, respectively. Malaria was induced in the mice by intraperitoneal administration of Plasmodium bergei (ANKA strain) on gestational day 9, and treatments were administered orally, once daily for 15 days starting from gestational day 11. On completion of the treatment, expression levels of IFN-gamma, IL-10, and Ki-67 were assessed using appropriate immunoassays. Administration of Syzygium cumini fruit fruit fraction resulted in a significant and a dose-dependent immunomodulatory effect in malaria infected pregnant mice, with the T3 group (1200 mg/kg) exhibiting the most pronounced modulation, with significant reduction in IFN-gamma, elevation of IL-10, and restoration of Ki-67 expression compared to infected controls. The effective modulation of IL-10, suppression of IFN-gamma, and promotion of Ki-67 by Syzygium cumini fraction indicate potential protective immunological and regenerative roles during malaria infection in pregnancy.Copyright © 2026 Khairoh et al.", "publicationTitle": "Tropical Journal of Natural Product Research", "publisher": "", "place": "", "date": "2026", "volume": "10", "issue": "1", "section": "", "partNumber": "", "partTitle": "", "pages": "6473-6476", "series": "", "seriesTitle": "", "seriesText": "", "journalAbbreviation": "", "DOI": "10.26538/tjnpr/v10i1.6", "citationKey": "", "url": "https://www.tjnpr.org/index.php/home/article/download/8040/7059 https://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=emexb&NEWS=N&AN=2043616964", "accessDate": "", "PMID": "", "PMCID": "", "ISSN": "2616-0684 2616-0692", "archive": "Embase Weekly Updates", "archiveLocation": "2043616964", "shortTitle": "", "language": "English", "libraryCatalog": "", "callNumber": "", "rights": "", "extra": "", "tags": [ { "tag": "*Ki 67 antigen/ec [Endogenous Compound]" }, { "tag": "*Plasmodium berghei" }, { "tag": "*Syzygium cumini" }, { "tag": "*Syzygium cumini extract/dt [Drug Therapy]" }, { "tag": "*gamma interferon" }, { "tag": "*gamma interferon/ec [Endogenous Compound]" }, { "tag": "*gamma1b interferon" }, { "tag": "*interleukin 10" }, { "tag": "*interleukin 10/ec [Endogenous Compound]" }, { "tag": "*malaria" }, { "tag": "*malaria/dt [Drug Therapy]" }, { "tag": "*mouse model" }, { "tag": "*murine model" }, { "tag": "*pregnancy" }, { "tag": "Bagg albino mouse" }, { "tag": "Leica RM2235" }, { "tag": "Olympus BX51" }, { "tag": "Plasmodium" }, { "tag": "adult" }, { "tag": "animal experiment" }, { "tag": "animal model" }, { "tag": "animal tissue" }, { "tag": "antimalarial activity" }, { "tag": "artenimol" }, { "tag": "artenimol/dt [Drug Therapy]" }, { "tag": "article" }, { "tag": "chloroform" }, { "tag": "controlled study" }, { "tag": "drug development" }, { "tag": "drug therapy" }, { "tag": "female" }, { "tag": "immune response" }, { "tag": "immunoassay" }, { "tag": "inflammation" }, { "tag": "intraperitoneal drug administration" }, { "tag": "ketamine" }, { "tag": "laboratory device" }, { "tag": "male" }, { "tag": "methanol" }, { "tag": "microscope" }, { "tag": "microtome" }, { "tag": "mouse" }, { "tag": "nonhuman" }, { "tag": "oral drug administration" }, { "tag": "piperaquine" }, { "tag": "piperaquine/dt [Drug Therapy]" }, { "tag": "plasmodium bergei" }, { "tag": "pregnancy" }, { "tag": "randomized controlled trial" }, { "tag": "rotary evaporator" }, { "tag": "stimulation" }, { "tag": "therapy" }, { "tag": "xylazine/ip [Intraperitoneal Drug Administration]" } ], "collections": [ "3KB9AC33" ], "relations": { "dc:replaces": "http://zotero.org/groups/251615/items/8J68H4MA" }, "dateAdded": "2026-03-03T21:19:38Z", "dateModified": "2026-04-07T20:19:48Z" } }, { "key": "BTPZZ5BN", "version": 12169, "library": { "type": "group", "id": 251615, "name": "CentreImage", "links": { "alternate": { "href": "https://www.zotero.org/groups/centreimage", "type": "text/html" } } }, "links": { "self": { "href": "https://api.zotero.org/groups/251615/items/BTPZZ5BN", "type": "application/json" }, "alternate": { "href": "https://www.zotero.org/groups/centreimage/items/BTPZZ5BN", "type": "text/html" } }, "meta": { "createdByUser": { "id": 14022664, "username": "TeodoraCHUSJ", "name": "", "links": { "alternate": { "href": "https://www.zotero.org/teodorachusj", "type": "text/html" } } }, "creatorSummary": "Khairoh et al.", "parsedDate": "2026", "numChildren": 0 }, "data": { "key": "BTPZZ5BN", "version": 12169, "itemType": "journalArticle", "title": "Antimalarial and Antioxidant Effects of Syzygium cumini (L.) Skeels (Myrtaceae) Fruit Fraction in Plasmodium berghei-Infected Pregnant Mice", "creators": [ { "creatorType": "author", "firstName": "M.", "lastName": "Khairoh" }, { "creatorType": "author", "firstName": "A.", "lastName": "Prayitno" }, { "creatorType": "author", "firstName": "L.", "lastName": "Maslachah" }, { "creatorType": "author", "firstName": "S.", "lastName": "Soetrisno" }, { "creatorType": "author", "firstName": "P.", "lastName": "Dirgahayu" }, { "creatorType": "author", "firstName": "E. P.", "lastName": "Pamungkasari" } ], "abstractNote": "Malaria in pregnancy constitutes a principal factor in the enduring prevalence of significant maternal and foetal illness and fatality. This study investigated the potential of Syzygium cumini (L.) Skeels (Myrtaceae) fruit fraction in modulating TNF-alpha, preserving placental spiral artery integrity, and improving foetal outcomes in Plasmodium berghei-infected pregnant mice. A true experimental design was conducted using second-trimester pregnant mice (n = 5 per group), which were infected with the P. berghei ANKA strain. Each mouse was administered an intraperitoneal dose of 0.2 mL phosphate-buffered saline comprising roughly 1 x 106 parasitized red blood cells obtained from donor mice with 20-30% parasitaemia. The animals were categorized into six groups: normal control (K1), infected untreated (K2), drug control treated with dihydroartemisinin-piperaquine (5 mg/kg body weight, oral), and three treatment groups receiving Syzygium cumini fruit (SCF) fraction at doses of 600 mg/kg (P1), 800 mg/kg (P2), and 1200 mg/kg (P3). Placental TNF-alpha levels were significantly reduced in all treatment groups compared with the infected control (K2), with the greatest reduction observed at 1200 mg/kg (P3, p < 0.05). Histological analysis revealed that P2 and P3 significantly improved spiral artery diameter and wall thickness, while P1 produced moderate changes. Foetal body length increased significantly in all treatment groups (p < 0.05), and foetal weight in P3 approached the normal control (K1). The (SCF) fraction demonstrated anti-inflammatory properties and improved placental function and supported foetal growth. These findings demonstrate its potential as a complementary natural therapeutic agent for managing malaria-associated complications during pregnancy.Copyright © 2026 Khairoh et al.", "publicationTitle": "Tropical Journal of Natural Product Research", "publisher": "", "place": "", "date": "2026", "volume": "10", "issue": "1", "section": "", "partNumber": "", "partTitle": "", "pages": "6477-6484", "series": "", "seriesTitle": "", "seriesText": "", "journalAbbreviation": "", "DOI": "10.26538/tjnpr/v10i1.7", "citationKey": "", "url": "https://www.tjnpr.org/index.php/home/article/download/8041/7060 https://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=emexb&NEWS=N&AN=2043685505", "accessDate": "", "PMID": "", "PMCID": "", "ISSN": "2616-0684 2616-0692", "archive": "Embase Weekly Updates", "archiveLocation": "2043685505", "shortTitle": "", "language": "English", "libraryCatalog": "", "callNumber": "", "rights": "", "extra": "", "tags": [ { "tag": "*Myrtaceae" }, { "tag": "*Plasmodium berghei" }, { "tag": "*Plasmodium berghei infection" }, { "tag": "*Syzygium cumini" }, { "tag": "*Syzygium cumini extract" }, { "tag": "*antimalarial activity" }, { "tag": "*antimalarial agent" }, { "tag": "*antioxidant" }, { "tag": "*antioxidant activity" }, { "tag": "*fruit" }, { "tag": "*histopathology" }, { "tag": "*placenta" }, { "tag": "*pregnancy" }, { "tag": "*tumor necrosis factor" }, { "tag": "DPPH radical scavenging assay" }, { "tag": "GraphPad Prism version 8.4.2" }, { "tag": "Ohaus PX124" }, { "tag": "Plasmodium falciparum" }, { "tag": "adult" }, { "tag": "anesthesia" }, { "tag": "animal cell" }, { "tag": "animal experiment" }, { "tag": "animal model" }, { "tag": "animal tissue" }, { "tag": "antimalarial agent" }, { "tag": "antioxidant" }, { "tag": "artenimol plus piperaquine" }, { "tag": "artenimol plus piperaquine/po [Oral Drug Administration]" }, { "tag": "artery diameter" }, { "tag": "article" }, { "tag": "body height" }, { "tag": "body weight" }, { "tag": "cell proliferation" }, { "tag": "chloroquine" }, { "tag": "controlled study" }, { "tag": "data analysis software" }, { "tag": "electronic balance" }, { "tag": "enzyme linked immunosorbent assay" }, { "tag": "erythrocyte" }, { "tag": "female" }, { "tag": "fetus" }, { "tag": "fetus growth" }, { "tag": "fetus outcome" }, { "tag": "fetus weight" }, { "tag": "flavonoid" }, { "tag": "gallic acid" }, { "tag": "gestational age" }, { "tag": "hematocrit" }, { "tag": "histology" }, { "tag": "histopathology" }, { "tag": "inflammation" }, { "tag": "interleukin 1beta/ec [Endogenous Compound]" }, { "tag": "ketamine/cb [Drug Combination]" }, { "tag": "liquid chromatography" }, { "tag": "malaria" }, { "tag": "mouse" }, { "tag": "natural product" }, { "tag": "nonhuman" }, { "tag": "oxidative stress" }, { "tag": "parasitemia" }, { "tag": "phosphate buffered saline" }, { "tag": "placenta" }, { "tag": "placenta function" }, { "tag": "plant extract" }, { "tag": "pregnancy" }, { "tag": "pregnancy complication" }, { "tag": "prevalence" }, { "tag": "second trimester pregnancy" }, { "tag": "thin layer chromatography" }, { "tag": "ultraviolet spectrophotometer" }, { "tag": "xylazine/cb [Drug Combination]" } ], "collections": [ "3KB9AC33" ], "relations": { "dc:replaces": "http://zotero.org/groups/251615/items/VT69L99C" }, "dateAdded": "2026-03-03T21:19:38Z", "dateModified": "2026-04-07T20:19:47Z" } }, { "key": "BGMK594P", "version": 12166, "library": { "type": "group", "id": 251615, "name": "CentreImage", "links": { "alternate": { "href": "https://www.zotero.org/groups/centreimage", "type": "text/html" } } }, "links": { "self": { "href": "https://api.zotero.org/groups/251615/items/BGMK594P", "type": "application/json" }, "alternate": { "href": "https://www.zotero.org/groups/centreimage/items/BGMK594P", "type": "text/html" } }, "meta": { "createdByUser": { "id": 14022664, "username": "TeodoraCHUSJ", "name": "", "links": { "alternate": { "href": "https://www.zotero.org/teodorachusj", "type": "text/html" } } }, "creatorSummary": "Srilekha et al.", "parsedDate": "2025", "numChildren": 0 }, "data": { "key": "BGMK594P", "version": 12166, "itemType": "journalArticle", "title": "EFFECT OF VITAMIN - D SUPPLEMENTATION ON SERUM VITAMIN D AND CALCIUM LEVELS IN URBAN AND RURAL PREGNANT WOMEN", "creators": [ { "creatorType": "author", "firstName": "V.", "lastName": "Srilekha" }, { "creatorType": "author", "firstName": "N.", "lastName": "Jagannath" }, { "creatorType": "author", "name": "Moulali" } ], "abstractNote": "Background: A normal level of vitamin D along with serum calcium levels during pregnancy is very important for foetal skeletal development, tooth enamel formation and perhaps general foetal growth and development. The present study aim is to find out the serum calcium levels in pregnant women based on their living area during the prenatal period. Material(s) and Method(s): It is a prospective study, done in 100 pregnant women who were allocated randomly into two groups based on living location. After giving 6000 IU of vitamin- D intervention, the calcium levels are measured at the end of 3 months and the variables were obtained before and after the intervention. Result(s): The mean difference of serum calcium levels 9.49+/-0.05, 8.97+/-0.025 in rural, urban pregnant women respectively after the vitamin-D supplementation [p<0.0001] after 3 months. Conclusion(s): Early intervention at reproductive age, fifth and seventh month of gestational age, regular screening and including in antenatal program, high dose of vitamin-D sup-plementation would be effective to prevent deficiency and improve the vitamin status.Copyright © Authors; 2025.", "publicationTitle": "Asian Journal Of Medical Research And Health Sciences", "publisher": "", "place": "", "date": "2025", "volume": "3", "issue": "3", "section": "", "partNumber": "", "partTitle": "", "pages": "62-66", "series": "", "seriesTitle": "", "seriesText": "", "journalAbbreviation": "", "DOI": "10.65605/a-jmrhs.2025.v03.i03.pp62-66", "citationKey": "", "url": "https://www.ajmrhs.com/index.php/journal/article/download/62/87 https://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=emedx&NEWS=N&AN=2037719129", "accessDate": "", "PMID": "", "PMCID": "", "ISSN": "2583-7761 (electronic) 2583-7761", "archive": "Embase Daily Updates", "archiveLocation": "2037719129", "shortTitle": "", "language": "English", "libraryCatalog": "", "callNumber": "", "rights": "", "extra": "", "tags": [ { "tag": "*calcium" }, { "tag": "*calcium blood level" }, { "tag": "*calcium mobilization" }, { "tag": "*gestational age" }, { "tag": "*hypocalcemia" }, { "tag": "*pregnancy" }, { "tag": "*pregnant woman" }, { "tag": "*rural area" }, { "tag": "*supplementation" }, { "tag": "*urban area" }, { "tag": "*vitamin D" }, { "tag": "*vitamin blood level" }, { "tag": "R software" }, { "tag": "adult" }, { "tag": "amelogenesis" }, { "tag": "article" }, { "tag": "bone development" }, { "tag": "drug therapy" }, { "tag": "enamel" }, { "tag": "female" }, { "tag": "fetus growth" }, { "tag": "gestational age" }, { "tag": "human" }, { "tag": "hypocalcemia" }, { "tag": "intervention study" }, { "tag": "major clinical study" }, { "tag": "pregnancy" }, { "tag": "prenatal care" }, { "tag": "prenatal period" }, { "tag": "prevalence" }, { "tag": "prospective study" }, { "tag": "screening" }, { "tag": "vitamin D deficiency" } ], "collections": [ "3KB9AC33" ], "relations": { "dc:replaces": "http://zotero.org/groups/251615/items/ZIFQIIBR" }, "dateAdded": "2026-03-03T21:19:32Z", "dateModified": "2026-04-07T20:19:47Z" } } ]